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ABSTRACT 
 
BACKGROUND 
Juvenile myoclonic epilepsy (JME) is a common type of idiopathic generalized epilepsy 
with onset occurring during adolescence. JME is life-long in most individuals, but 
around 80% gain good seizure control with anti-epileptic drugs (AEDs). Impairments in 
executive function are consistently demonstrated in JME and are similar to those 
reported in patients with cluster B personality disorders. Moreover, a high incidence of 
personality and affective disorders has been reported in JME. This research aimed to 
profile drug-refractory JME, and address whether the executive dysfunctions and 
maladaptive behaviour reported in JME patients is related.  
 
METHODS 
A total of 60 patients with drug-refractory JME were administered tests of intellect, 
memory and executive functions. Anxiety, depression, personality traits, impact of 
epilepsy and perceived cognitive effects of AEDs were measured.  
 
RESULTS 
The sample as a whole presented with poorer neuropsychological functioning than 
published norms. Abnormal personality traits and high levels of anxiety were 
associated with the worse intellectual and executive functioning. Half of the cohort 
exhibited moderate to severe anxiety symptoms.  
 
CONCLUSIONS  
This research indicates that specific patterns of executive dysfunctions are related to 
maladaptive behaviour in drug-refractory JME. This research has identified a possible 
subgroup of patients that present with a more severe type of JME, and may be 
distinguished by genetic stratification. Finally, the current research confirms the 
breadth of deficits in drug-refractory JME, and highlights that it is more than just 
executive function difficulties that must be targeted to support individuals through 
education and employment.  
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CHAPTER ONE – INTRODUCTION   
 
 
 
Epilepsy is a neurological disorder that is characterised by an increased predisposition 
to the occurrence of a transient event of abnormal paroxysmal discharges, in a group of 
cerebral neurons or the majority of the cortex [1]. This activity is known as an epileptic 
seizure. People with epilepsy (PWE) have a predisposition to epileptic seizures and 
must experience at least two to be diagnosed with the disorder [2]. It is associated with 
disturbances in neurobiological, cognitive and psychosocial functioning [3]. Epilepsy is 
divided into syndromes, which are usually defined by the area of the brain the activity 
starts in and spreads to (i.e. primary generalised, partial and secondary generalised), 
by the types of seizures experienced (e.g. myoclonic, tonic-clonic, absent, tonic, atonic), 
the age of onset and aetiology [1]. 
 
Patients who have seizures that have non-focal onset (i.e. generalised) make up 30-
40% of cases [4], with the majority of these exhibiting seizure with no identifiable 
cause, but a genetic predisposition. This is called idiopathic generalised epilepsies (IGE) 
[5]. IGE is the most common form of generalised epilepsy, with several syndromes that 
fall under the IGE title [6]. Patients with IGE usually have normal intellectual 
functioning, and have no visible abnormalities on brain scans [6].   
 
Juvenile Myoclonic Epilepsy (JME) is an IGE that accounts for 6-12% of all epilepsy 
cases [7] and approximately 26% of IGE cases [8]. The onset of JME can occur between 
the ages of 6 and 22 years, with 50% of cases presenting between the ages of 13-16 
years [9]. The disorder is thought to be lifelong [10] with the majority of patients 
responding to treatment [11].  
 
JME typically presents with bilateral, arrhythmic myoclonic jerks that can be single or 
repetitive, and usually involve the upper extremities [12]. JME is also often associated 
with generalised tonic-clonic seizures in around 80-97% of patients, and absence 
seizures in 12-54% [9]. Nevertheless myoclonic seizures must be present for a 
diagnosis of JME [9]. An EEG characterised by polyspike-and-wave complexes is 
commonly found in JME patients.  
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It is well documented that patients with JME show impairments in neuropsychological 
assessments [7, 11-16]. These impairments are multi-factorial and encompass 
pathophysiology, treatment, psychosocial factors, seizure -type, -duration, -severity and 
–onset (illustrated in figure 1.1).  However, past research has assessed patients with 
controlled JME or mixed samples of controlled and refractory patients. The current 
thesis aimed to profile purely refractory JME to investigate whether these patients have 
worse cognition and if clinical characteristics have a bigger impact.  
 
 
 
Adapted from [17] 
Figure 1.1 The multiple and interacting factors that contribute to each individual 
patient’s epileptic disorder 
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Impairments in executive functions are the most consistent finding in JME [7, 11-13, 
16]. The executive dysfunctions found are similar to those reported in patients with 
personality disorders [18, 19]. Moreover, researchers have described structural and 
functional abnormalities in the frontal lobes of JME [20-22], which have also been 
reported in patients with personality disorders [23, 24]. 
 
It has been hypothesised that JME is not one disorder but several and past research has 
attempted to categorise JME patients into subgroups [25]. Research has found different 
levels of neuropsychological dysfunction, psychiatric disorders and different 
personalities in JME patients [26, 27]. One study proposed that distinct behavioural 
differences may be a result of specific brain dysfunctions caused by different epilepsies 
[28]. The current thesis aimed to examine whether executive dysfunctions and 
maladaptive behaviour were related, and if the different levels of dysfunction could be 
explained by different patterns of behaviour.  
 
The objectives of the current thesis are to: 
 
1. Verify the neuropsychological profile of refractory JME. 
2. Examine the contribution of age of onset, duration of epilepsy, education, type 
of seizures, treatment, mood, impact of epilepsy and subjective view of 
cognitive functioning.   
3. Examine whether refractory JME patients with high levels of anxiety and/or 
depression are more impaired on neuropsychological functioning tests than 
those with normal levels of anxiety and/or depression 
4. Examine the relationship between personality and executive dysfunctions. Aim 
to provide evidence for frontal lobe involvement, and for the hypothesis that 
there is more than one type of JME.  
 
An overview of epilepsy as a whole will be discussed in Chapter two. Chapter three will 
give a more in depth description of JME including the possible causes, diagnosis, 
treatment and prognosis. 
 
Past research that has investigated the neuropsychological dysfunctions in JME will 
discussed in Chapter four. In addition, an analysis of the research that has investigated 
14 
 
the possible causes of these deficits will be given here. The chapter will discuss each of 
the multiple factors given above.  
 
Chapter five will provide a detailed discussion of the current theses aims and 
hypotheses. The methodology employed to meet these aims will be given in Chapter six. 
This will be followed by the results of each of the hypotheses in Chapter seven to 
twelve. This thesis will end with a discussion of the findings from the current study in 
relation to past research, and future practise and investigation. Any limitations will also 
be given here. 
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CHAPTER TWO – EPILEPSY  
 
 
 
Epilepsy has been documented since ancient times with reference to those who are 
possessed found in ancient scripture [29]. The WHO state that Epilepsy is the oldest 
condition known to mankind [30], and still remains the most common neurological 
disorder directly affecting 50 million people worldwide at any given time [31].  
 
The word epilepsy comes from the Greek verb ελαμβανειν (eng: elamvaneen), which 
translated means “to be seized by forces from without” [32]. Epilepsy was first described 
as a disorder of the brain in an essay presumed to have been written by Hippocrates 
titled The Sacred Disease, in which he described a generalised epileptic seizure [29]. 
However, historically epilepsy was thought to be a punishment from God. Yet still today 
stigma remains, especially in developing countries where some people believe epilepsy 
is an act of witchcraft or that it is infectious [29].  
 
It wasn’t until the 19th century that the first steps of contemporary thinking about 
epilepsy were taken [33]. This step was taken by John Hughlings Jackson; through 
detailed observations of individual cases he defined epilepsy as “An occasional, 
excessive, and disorderly discharge of nerve tissue.” [32]. He also went on to highlight 
that epilepsy can affect anyone, at any age and from countless causes, “This discharge 
occurs in all degrees; it occurs with all sorts of conditions of ill health at all ages, and under 
innumerable circumstances.” [32].   
 
The accepted definition of epilepsy and of seizures provided by the International 
League Against Epilepsy (ILAE) is given in table 2.2 below.  
 
2.1 HOW DO SEIZURES HAPPEN?  
 
The events that lead to the ictal state are not fully understood, but experimental models 
of epilepsy show that seizures are preceded by massive depolarisation of neurons, 
which lead to a series of synchronised action potentials. This is called the paroxysmal 
depolarisation shift (PDS) [32]. The PDS can be due to several mechanisms, these may 
16 
 
include; changes in extracellular ion concentrations, disturbances in neuronal 
membranes, disturbances in excitatory or inhibitory neurotransmitters, and changes in 
K⁺ or Ca²⁺ currents [32] (See Figure 2.1 below for an illustration of the possible 
processes involved in epileptogenesis). These changes may occur in an epileptiform 
focus (may be responsible for focal seizures), or the action potentials may spread 
through synaptic pathways (may be responsible for generalised seizures). Many anti-
epileptic drugs (AEDs) act on one of these mechanisms. For example Carbamazepine’s 
(CBZ) primary mode of action is to inhibit voltage-gated NA⁺ channels [34]. 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from [32].   PDS: paroxysmal depolarisation shift, EPSP: Excitatory postsynaptic 
potentials, IPSP: Inhibitory postsynaptic potentials.  
 Figure 2.1 Possible mechanisms of interictal and ictal events 
 
2.2 DIFFERENTIAL DIAGNOSIS 
 
It can be a challenge to distinguish and diagnose epilepsy and non-epileptic paroxysmal 
events [35]. Studies have reported that a concerning 20-30% of patients are 
misdiagnosed with epilepsy [36, 37]. The most common conditions to be misdiagnosed 
as epilepsy are psychogenic non-epileptic attacks and syncope [36, 37]. Table 2.1 below 
highlights the possible differential diagnosis of epilepsy. 
NORMAL EEG 
INTERICTAL 
EEG 
ICTAL EEG 
R
E
C
O
V
E
R
Y 
E
P
I
L
E
P
T
O
G
E
N
E
S
I
S 
 Excitation  
 Inhibition 
  K⁺ 
  Ca⁺² 
 
PDS –spike/sharp waves 
Potentiation of EPSPs 
Reduction in IPSPs 
Inability to clear K⁺ 
Inhibition of K⁺ 
currents 
 Inhibition 
 Noradrenaline  
 Ca⁺² 
Clearance of K⁺ 
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Table 2.1 Possible differential diagnosis of epilepsy 
  
Psychogenic non-epileptic attacks  
Syncope 
Hypoglycemia 
Panic attacks 
Paroxysmal movement disorders Acute dystonic reactions 
Hemifacial spasm 
Non-epileptic myoclonus 
Sleep disorders Parasomnias 
Cataplexy 
Hypnic jerks 
Transient ischemic attacks 
Migraines 
Transient global amnesia 
 
                                                                               Adapted from [36] 
 
2.3 DEFINITION AND CLASSIFICATION OF EPILEPSY 
 
 
Table 2.2 Definitions provided by the International League Against Epilepsy (ILAE) 
  
A seizure  A transient occurrence of signs and/or 
symptoms due to abnormal excessive or 
synchronous neuronal activity in the 
brain. 
Epilepsy A brain disorder characterised by an 
enduring predisposition to generate 
epileptic seizures and by the neurologic, 
cognitive, psychological and social 
consequences of this condition. 
  Adapted from [3] 
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A person is only said to have epilepsy following the occurrence of at least two 
unprovoked seizures without any acute provoking event e.g. infection, brain trauma, 
drugs or alcohol withdrawal. A seizure involving any precursory event is referred to as 
provoked seizures (also known as symptomatic or reactive seizures), whereas a true 
epileptic seizure is referred to as unprovoked [1, 2].  
 
Epilepsy is not a single disease, but a broad term that is used to describe a propensity 
to unprovoked seizures arising from a wide range of pathological causes [17].  
Epilepsies are classified in two ways; firstly by the type of seizures experienced, focal or 
generalized, and secondly by particular patterns of symptoms and patient 
characteristics, which are clustered into syndromes [2, 38].  
 
2.3.1 EPILEPTIC SEIZURES 
Defining seizure types is the first step in classification, but nonetheless can still be 
useful [38]. All seizures can be grouped into two primary types, focal and generalised.   
 
Copyright Oxford University Press, with permission [2]  
 
Figure 2.2 Brain involvement during different types of seizures 
 
 
Focal seizure 
Focal seizure with 
secondary generalisation  
Primary generalised 
seizure 
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2.3.1.1 Focal (partial) seizures 
Focal seizures are characterised by the area of cortex the discharge of abnormal nerve 
cells originates [2]. The initial activation of focal seizures takes place in only part of one 
cerebral hemisphere [38], and can be in any of the four lobes (frontal, temporal, 
parietal and occipital). A seizure originating in the motor cortex of one of the frontal 
lobes causes contralateral contractions of the muscle. The most likely nerve cells the 
discharge may start in are those that control the index finger and thumb, corner of the 
mouth and big toe, as there are more nerve cells assigned to these muscles [2]. Seizures 
occurring in other lobes of the brain may be less obvious. A seizure in the parietal lobe 
may merely cause a perception of pins and needles or numbness in the opposite side of 
the body. Similarly, temporal lobe seizures may result in the feeling of déjà vu or an 
unpleasant smell or hallucination  [2].  
 
Focal seizures may or may not result in a loss of consciousness. Seizures in which 
consciousness is maintained are referred to as simple partial seizures, while those that 
result in loss of consciousness are referred to as complex partial seizures. Recently it 
has been proposed that both types of seizures should be referred to only as focal 
seizures with the addition of a very detailed description of what happened [2, 38]. 
However, the terms simple and complex partial seizures continue to be used.  
 
Focal seizures may also develop into secondary generalised tonic-clonic seizures, in 
which the paroxysmal discharge spreads to central nerve cells from the original focal 
point. From these centralised cells the discharge spreads throughout the brain [2].     
 
2.3.1.2 Generalised seizures 
Generalised seizures can be convulsive or non-convulsive, and involve widespread 
bilateral discharges [39]. There are three main types of generalised seizures, namely 
generalised tonic-clonic seizure (GTCS), typical absence seizures (absences) and 
myoclonic seizures (myoclonus) [38].  
 
Tonic-clonic seizures 
GTCS are the hallmark convulsive seizures, known in lay terms as fits. They differ from 
secondary generalised seizures by their point of origin. GTCS begin in central nerve 
cells, which result in widespread involvement of the cerebral cortex. Nerve cells in the 
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brain stem connected to the cerebral cortex enable direct transmission to muscle 
fibres, resulting in the characteristic muscle contractions seen in GTCS [2, 39].  
 
Most GTCS are sudden and happen without warning other than possibly precursory 
myoclonus or absences, however these may be so brief that the person or onlookers 
may be unaware of them [38]. GTCS begin with the tonic stage (contraction), in which 
the muscles of the body contract and become rigid causing the person to collapse. 
People often bite their tongue or inside of their cheek as their jaw contracts, and grunt 
or cry as the respiratory muscles contract, and air is expelled. Blood oxygen is used up 
rapidly with no coordinated breathing movements, resulting in cyanosis (the person 
becoming a dusky blue colour). Increased pressure in the thorax causes vasodilatation 
in the face worsening the look of cyanosis. The person may dribble as normal 
swallowing ceases resulting in a build up of saliva. Incontinence may also occur. [2, 32]. 
 
The clonic stage (convulsive) starts within one-two minutes of the tonic stage starting. 
This phase involves rhythmic movements of gradually increasing frequency of the 
limbs and trunk muscles. The frequency increases over 30-60 seconds, and then 
gradually decreases over one-two minutes. Overall the entire seizure usually lasts 
approximately three-five minutes, following which the person regains consciousness, 
yet remains confused for some time afterwards. Many people will then sleep for at least 
a couple of hours, and awake afterwards feeling lethargic and stiff [2, 32].    
 
Absence Seizures 
Absences were formally known as petite mal, which translated means ‘little illness’. 
This confuses people, and thus is no longer used in clinical practise. Absences can go 
unnoticed for a long time due to their brevity, sudden onset and conclusion. During the 
seizure the person will abruptly stop what they were doing or saying. Often a person 
may have a dazed expression, flicker their eyelids, lick their lips, and possibly fidget 
with their hands. Less often a person’s head may drop slightly forward, but posture is 
maintained. [2, 32]. 
 
On average a person will experience 10-20 absences a day; however some people will 
experience over 50 a day. Absences predominately occur in childhood and adolescence, 
although they can continue into or very rarely start in adulthood [2]. In order to 
diagnose absences an EEG showing short bursts (usually 5-10 seconds, but occasionally 
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up to 20 seconds) of rhythmic generalised spike and slow wave activity is required 
[32]. 
 
For a list of all the known focal and generalised seizures, including the rarer types 
please see Table 2.3 below.   
 
Table 2.3 Epileptic seizure types  
  
Focal seizures 
 
  
Focal sensory 
Focal motor  
Gelastic  
Hemiclonic  
Secondary generalised  
Generalised seizures Tonic-clonic  
Clonic  
Tonic 
Typical absence 
Atypical absence 
Myoclonic absence 
Spasms 
Myoclonic 
Eyelid myoclonia (with and without 
absences) 
Negative myoclonus 
Atonic  
Reflex (in generalised epilepsy 
syndromes) 
Adapted from [40] 
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2.4 EPILEPSY SYNDROMES 
 
Many people experience similar patterns of symptoms, onset, prognosis etc. and thus 
these particular patterns have been classified into epileptic syndromes. A list of 
syndromes was developed by the ILAE in 1989 and a proposal for an updated 
classification was published in 2001 [40], but has not yet achieved international 
acceptance. Epileptic syndromes have been divided into idiopathic (presumed genetic), 
symptomatic (identifiable cause) and probably symptomatic (synonymous to 
cryptogenic – an unidentifiable cause) [41]. Table 2.4 provides a list of the current ILAE 
classified epileptic syndromes divided in whether brain involvement is focal or 
generalised. These are then further divided by aetiology (idiopathic, symptomatic and 
probable symptomatic).        
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Table 2.4 Current ILAE classified epileptic syndromes   
   
Focal Idiopathic  Benign childhood epilepsy 
with centro-temporal spikes 
Childhood epilepsy with 
occipital paroxysms 
Primary reading epilepsy 
Symptomatic  Rasmussen syndrome 
Syndromes characterised by 
seizures with specific modes 
of precipitation 
Neocortical epilepsies  
Probable symptomatic Same syndromes as Focal 
symptomatic, but with 
unidentifiable aetiology. 
Generalised  Idiopathic  Benign neonatal convulsions 
Benign myoclonic epilepsy in 
infancy 
Childhood absence epilepsy 
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy 
Epilepsies with GTCS 
Reflex epilepsies 
Symptomatic or probable 
symptomatic 
West syndrome (infantile 
spasms) 
Lennox-Gastaut syndrome  
Landau-Kleffner syndrome 
Epilepsy with myoclonic-
astatic seizures 
Epilepsies with myoclonic 
absences 
Adapted from [40] 
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2.5 AETIOLOGY 
 
2.5.1 WHAT CAUSES EPILEPSY? 
There are many potential causes of epilepsy, yet for many patients the cause of their 
epilepsy remains unknown. In these cases the cause is assumed to be genetic or 
cryptogenic. A large 50 year prospective study conducted in Minnesota, USA reported 
68% of the patients were presumed to have epilepsy with an unknown cause 
(idiopathic and cryptogenic). The remaining 38% of epilepsies were caused by central 
nervous system (CNS) disease, trauma, prenatal and perinatal development, 
cardiovascular disease (CVD), or other [42]. Figure 2.3 below illustrates the 
distribution of the causes found in this study. These figures are similar to those found a 
decade later in another USA study, a UK study and a Brazilian study, who reported 
65%, 61% and 59.5% respectively had an unknown (presumed cryptogenic or 
idiopathic) causes [2, 43]. 
 
 
 
Produced using data from [42]. CNS: Central nervous system, CVD:  Cardiovascular disease.                   
 
Fig 2.3 Presumed predisposing causes of epilepsy.  
 
 
68% 
11% 
5% 
5% 
4% 
4% 3% 
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IDIOPATHIC/CYPTOGENIC 
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DEVELOPMENTAL 
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BRAIN TUMOR 
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Since these studies there have been great advances in imaging, consequently many of 
the unknown group now would be found to have underlying brain abnormalities that 
were not possible to see 20 years ago.  
 
Genetic research has also become much more advance, and we now know the genes 
that are responsible for all of the classified Mendelian epilepsies such as benign familiar 
neonatal convulsions and benign adult familiar myoclonic epilepsy [44]. However the 
genes involved in non-Mendelian epilepsies such as the IGEs remain predominately 
unidentified, as complex inheritance of two or more genes are believed to be involved. 
 
One aspect of the aetiology of epilepsy that is clear is that the earlier in life you have 
epilepsy the more likely genes are involved, whereas trauma, or brain disease is the 
most likely cause in adults [30]. The most common causes of epilepsy throughout a 
lifetime are genetics, pre-natal development, anoxia, trauma, tumours, infectious 
disease, and finally degenerative disorders [2].   
 
 
2.6 EPIDEMIOLOGY AND PROGNOSIS 
Epidemiological studies are important for our understanding of epilepsy, illustrating its 
magnitude and highlighting patterns in PWE revealing fundamental aetiological 
information. Additionally they enable identification of risk factors for developing 
epilepsy, and future prognosis [45]. However due to the cost in time and complexity 
very few worldwide population studies have been conducted [46]. Of the studies that 
have been carried out it is clear that epilepsy effects all races, both genders and all ages 
[47]. However, most people are diagnosed between infancy and adolescence or in older 
age (Figure 2.4 illustrates this nicely). Although in developing countries onset is 
predominately in childhood [31]. 
 
Epilepsy has been reported to affect 1-2% of the population worldwide [48], and 
affecting around 50 million people at any given time [30]. Around 400 per 100,000 
people in the UK have active epilepsy [49]. Everyone has a 10% lifetime risk of having a 
single seizure, and a 3% lifetime risk of developing epilepsy [50]. 
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Figure 2.4 Prevalence, cumulative incidence and incidence rates of epilepsy [51] 
 
2.6.1 PREVALENCE  
Prevalence is the number of cases of a disorder within the general population at any 
given time [30]. It has been estimated that the worldwide prevalence of epilepsy is 8.2 
per 1000 [30]. Record based epidemiology studies have reported age-adjusted 
prevalence rates per 1000 of 7.1 in the United States, 5.5 in the United Kingdom, 7.1 in 
Thailand and 17.6 in Chile [47]. Similar rates have been reported in door-to-door 
survey studies, which also show Central and South America have the highest reported 
prevalence of epilepsy in the world [47]. One review paper concluded that overall 
prevalence is lower in developed countries, with the lowest reported prevalence in 
Asia. However the low prevalence in Asia may be due to the high stigma associated with 
epilepsy in this region [47].   
 
2.6.2 INCIDENCE 
Incidence is the number of new cases of a disorder in the general population at any 
given time [30]. It has been estimated that the incidence of epilepsy in developed 
countries is approximately 50 per 100,000 per year. However this number has been 
estimated to be double in developing countries, with reports of approximately 100 per 
100,000 per year [30]. Reports from independent age-adjusted studies from across the 
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world report incidence rates of 16-51 in North America, 26-47 in Europe, 35 in Asia, 
42-51 in Africa and 111 in Central and South America per 100,000 [47].     
 
The trend for higher rates of epilepsy in developing countries may be explained by an 
increased risk of brain disease/infection such as meningitis, neurocysticerosis, malaria, 
pre- and peri-natal complications and malnutrition. These can result in permanent 
brain damage, which often leads to epilepsy [30]. 
 
2.6.3 PROGNOSIS  
The outlook for many people with epilepsy is quite positive with reports of 70% 
achieving seizure control. For many once seizure control is achieved, medication can be 
stopped and the individual can remain in remission for the rest of their lives. However 
despite the positive prognosis, due to the cost of treatment and stigmatisation of 
epilepsy around 3 in 4 people with epilepsy do not receive any treatment. The majority 
of these cases are in developing countries [31]. For the 30% who cannot be controlled 
with current treatment their health, psychosocial, education, job and general quality of 
life can be severely diminished [30].   
 
Epilepsy is also associated with a higher mortality rate. There are five causes of this 
increased mortality 1) seizure related, such as respiratory/cardio-respiratory arrest, 
drowning, severe head trauma etc.; 2) aetiology related, such as brain tumour/disease; 
3) Treatment related, such as epilepsy surgery or medication;  4) Suicide; 5) Sudden 
unexplained death in epilepsy (SUDEP) [52]. 
 
2.6.4 TREATMENT 
There are two main treatment options for people with epilepsy, antiepileptic drugs and 
surgery. An alternative treatment option that is mainly used with infants and children 
is known as the Ketogenic diet.  
 
2.6.4.1 AEDs: Efficacy and side effects 
There are almost 20 licensed antiepileptic drugs; however 30% of patients still remain 
refractory, while many controlled patients experience adverse side effect [53].  AEDs 
developed before 1994 are known as the old or 1st generation AEDs, the common ones 
include Phenytoin (PHT), Valproate (VPA), Carbamazepine (CBZ), Ethosuximide (ETX), 
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Primidone (PRM) and Phenobarbital (PB) [1] (for full list of AEDs, see Table 2.5 below). 
A large prospective study by the Veteran Administration showed that CBZ and PHT had 
the greatest success in controlling seizures, and overall 70% of patients were 
controlled on monotherapy with one of the older AEDs [54]. 
 
The AEDs developed after 1994 are known as the newer or 2nd generation AEDs, and 
some have been found to have similar efficacy to the older drugs while overall being 
safer and more tolerable [53]. The newer AEDs include, Lamotrigine (LTG), 
Levetiracetam (LEV), Topiramate (TPM) and Zonisamide (ZNS) (for full list see Table 
2.5 below).  A study that compared the newer AEDs with the older AEDs found for 
patients with focal seizures, the newer drug LTG was clinically better than the older 
generation drug CBZ [55]. For patients with generalised seizures however the older 
AED, VPA was found to have the most efficacy and tolerability compared to the newer 
AEDs LTG and TPM, respectively [4].  Table 2.6 below shows which AEDs are the first 
and second line treatments for different seizure types.  
 
Table 2.5 1st and 2nd generation AEDs 
1st generation  2nd generation 
Acetazolamide Phenytoin  Eslicarbazepine acetate 
Carbamazepine Gabapentin 
Clobazam Lacosamide  
Clonazepam Lamotrigine 
Ethosuximide  Levetiracetam 
Phenobarbital  Oxcarbazepine  
Primidone Pregabalin 
Valproate Retigabine  
Vigabatrin Rufinamide 
 Tiagabine 
 Topiramate  
 Zonisamide 
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Table 2.6 AEDs used for first and second line treatment of individual seizure types 
Seizure type First line AEDs 
Adjunctive 
AEDs 
Other AEDs 
that may be 
considered in 
tertiary care 
AEDs that 
should not be 
offered (may 
worsen 
seizures 
Generalised 
tonic-clonic  
Carbamazepine 
Lamotrigine 
Oxcarbazepine   
Valproate 
Clobazam* 
Lamotrigine 
Levetiracetam  
Valproate 
Topiramate 
 If patient 
experiences 
absence or 
myoclonic 
seizures, or if 
JME is 
suspected do 
not offer: 
Carbamazepine 
Gabapentin 
Oxcarbazepine 
Phenytoin 
Pregabalin 
Tiagabine 
Vigabatrin  
Tonic or 
atonic 
Valproate Lamotrigine* Rufinamide* 
Topiramate* 
Carbamazepine 
Gabapentin 
Oxcarbazepine 
Pregabalin 
Tiagabine 
Vigabatrin 
Absence Ethosuximide,  
Lamotrigine* 
Valproate 
Ethosuximide,  
Lamotrigine* 
Sodium 
Valproate 
Clobazam* 
Clonazepam 
Levetiracetam* 
Topiramate* 
Zonisamide* 
Carbamazepine 
Gabapentin 
Oxcarbazepine 
Phenytoin 
Pregabalin 
Tiagabine 
Vigabatrin 
Myoclonic Levetiracetam* Levetiracetam Clobazam* Carbamazepine 
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Topiramate* 
Valproate  
Topiramate* 
Valproate 
Clonazepam 
Piracetam 
Zonisamide* 
Gabapentin 
Oxcarbazepine 
Phenytoin 
Pregabalin 
Tiagabine 
Vigabatrin 
Focal 
seizures 
(including 
secondary 
generalised 
tonic clonic) 
Carbamazepine,  
Lamotrigine 
Levetiracetam 
Oxcarbazepine  
Valproate   
 
Phenobarbital, 
Phenytoin, 
Primidone, 
Tiagabine  
Eslicarbazepine 
acetate 
Lacosamide 
Phenobarbital 
Phenytoin 
Pregabalin* 
Tiagabine 
Vigabatrin 
Zonisamide* 
 
Prolonged 
or repeated 
seizures 
and 
convulsive 
status 
epilepticus 
in the 
community 
Buccal 
Midazolam, 
Rectal 
Diazepam**, 
Intravenous 
Lorazepam  
   
Convulsive 
status 
epilepticus 
in hospital 
Intravenous 
Lorazepam,  
Intravenous 
Diazepam,  
Buccal 
Midazolam 
Intravenous 
Phenobarbital, 
Phenytoin 
  
Adapted from NICE guidelines [56]  
* At the time of NICE guidelines publication this drug did not have UK marketing authorisation 
for this indication and/or population.  
** At the time of NICE guidelines publications this drug did not have UK marketing authorisation 
for this indication and/or population.  
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All pharmacological treatments have side effects and AEDs are no exception. Some 
AEDs are associated with mild adverse effects such as hair loss, dry mouth and weight 
gain, but others can have very severe even fatal side effects such as liver dysfunction, 
thrombocytopenia and hyperammonaemia [2, 53].  
 
There are three main types of adverse effects an individual may experience and include, 
allergic or hypersensitivity (idiosyncratic), dose-related and chronic [2]. Around 5% of 
patients will experience an idiosyncratic reaction that usually results in a widespread, 
itchy rash. Common drugs that are associated with this are CBZ, LTG, PB and PHT. 
Dose-related side effects are caused by taking a dose too high or starting a drug too 
quickly. Side effects often caused by dose include drowsiness, unsteadiness, nausea, 
and blurred or double vision. Finally chronic side effects are ones that build up over 
time and are long lasting. These include memory impairments, changes in mood and 
behaviour, thickening gums, and excessive vitamin D metabolism. Additionally the most 
concerning chronic side effect of AEDs is the possible teratogenic effects, which include 
physical malformations and cognitive impairments [2]. Valproate has been significantly 
associated with these teratogenic effects [57-59]. 
 
Self report questionnaires have found that memory problems, tiredness and difficulty 
in concentrating are the most common adverse effects of AEDs. Additionally patients on 
polytherapy consistently report more adverse effects than those on monotherapy [60, 
61]. However when patients are asked directly by the prescribing physician fewer 
adverse effects are reported than may be present [62]. One study assessed the use of 
standardised self-report tools in the clinic. They found an association between adverse 
events profile (AEP) and a 2.8 fold increase in AED regime change, without significant 
change in seizure frequency. Further, patients who completed the AEP reported 
improved quality of life after four months and significant drops in AEP scores were 
found [63]. 
 
 
2.6.4.2 Epilepsy Surgery 
Curative surgery is predominately aimed at patients with focal epilepsies. Surgery will 
usually only be considered in these patients if they are refractory to drug treatment and 
their seizures are severe enough to have a negative impact on their quality of life [1]. 
For those patients who are eligible the outlook is a reasonably positive one. 
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Approximately 60-70% of patients who have epilepsy surgery will become seizure free, 
while a further 10-20% will see a great improvement in the amount of seizures they 
experience [2]. Table 2.7 below outlines the current epilepsy surgical procedures.  
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Table 2.7 Current epilepsy surgical procedures outline and outcome 
Procedure  Brief description Outcome 
Vagus Nerve stimulation  For those unable or 
unwilling to have surgery. 
A pulse generator is 
implanted under the skin 
below the collar bone. 
Spiral electrodes are then 
wrapped around the Vagus 
nerve, which conduct the 
electrical signal to the 
Vagus nerve from the pulse 
generator. It is thought to 
desynchronise cortical 
activity. 
25-30% reduction in 
seizure frequency 
Lesionectomy  Involves removal of lesion 
and depending on location 
1-2cm of surrounding 
tissue. Common lesions 
include tumours, vascular 
malformations, scars, or 
areas of focal atrophy. 
80-86% seizure free 
Lobectomy  Involves removal of 
portion or entire lobe in 
which the focus of 
epileptogenic activity lies.  
Frontal lobe – 60-76% 
seizure free. 
Temporal lobe- 66% 
seizure free, 19% 
significant improvement. 
Parietal lobe – 64-80% 
seizure free. 
Occipital lobe – 60-72% 
seizure free. 
Hemispherectomy Usually performed in 
children with non-focal 
seizures that are severe 
and intractable. Involves 
60-90% seizure free. 
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disconnection (and much 
removal) of the entire 
cortex of a single 
hemisphere. 
Corpus Callosotomy Involves severing of part of 
or all of the corpus 
callosum, which is the 
structure that connects the 
2 hemispheres.   
Aims to reduce not 
eliminate seizures. 50-80% 
experience significant 
improvements in seizure 
frequency. 
Multiple subpial 
transection 
Involves cutting 
intracortical fibres at 5mm 
intervals.  
When used on its own only 
about a third of patients 
are seizure free. When 
used in conjunction with 
resection 48% may become 
seizure free, while a third 
experience a significant 
reduction in seizure 
frequency. 
Adapted from [1] 
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2.6.4.3 Ketogenic Diet  
The Ketogenic diet is an alternative treatment option, which involves a period of 
starvation in order to create a state of ketosis. This is then followed by a diet high in fat 
and low in carbohydrates and protein. Usually a ratio of 3-4 parts fat to 1 non fat is 
used. The idea of diet as a treatment of epilepsy actually dates back to the 5th century 
BC in reports by Hippocrates. Fasting is also mentioned in the bible (Matthew 17:14-21 
and Mark 9:14-29) as a cure for seizures, with reference to Jesus telling his disciples 
that “demons” can only be cleansed by prayer and fasting [64].  
 
The diet is thought to increase seizure threshold by increasing the brains energy 
reserves, which in turn increases neuronal stability [1]. It is predominately used in 
children with intractable generalised seizure, but has shown some success in adults 
and patients with partial seizures. Two-thirds of children on this diet either become 
seizure free or experience a 90% reduction in seizures, while a third show no 
improvement [1].     
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CHAPTER THREE – JUVENILE MYOCLONIC 
EPILEPSY 
 
“Every morning, when I had to get up, everything fell out of 
my hands. I broke innumerable toothbrush glasses, cups, 
etc.” 
 
A patients own account in a letter written to Janz [65] 
 
 
 
A detailed case study of a patient with JME was first written by Herpin in 1867 when he 
observed myoclonic jerks in his son referring to them as “secousses” [66]. Others 
before and after him discussed the symptoms, but the syndrome was not classified until 
1957 when Janz and Christian described the disorder in detail, and termed it ‘impulsive 
petit mal’ [66, 67]. It was later known as Juvenile Myoclonic Epilepsy of Janz, but was 
soon shorted to Juvenile Myoclonic epilepsy or JME by the International League Against 
Epilepsy [68].   
 
3.1 DEFINITION OF JME 
 
JME is an idiopathic generalised epilepsy. It is defined as the onset of myoclonic jerks 
(usually bilaterally in the upper extremities) in adolescents, coupled with irregular 
interictal EEG characterised by polyspike-and-wave complexes. In addition to 
myoclonic seizures people with JME also often experience tonic clonic seizure (80-97% 
of patients) and less commonly, absence seizures (12-54% of patients) [7, 9]. 80% of 
patients are well controlled on AEDs, particularly VPA; however relapse is high if 
pharmacological treatment is stopped even when a patient hasn’t experienced a seizure 
for years. It is believed to be lifelong but not progressive, and has a strong genetic 
aetiology [10, 69]. Table 3.1 below briefly summarises the features of JME, all of which 
will be discussed throughout the current chapter.     
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Table 3.1 Common features of Juvenile Myoclonic Epilepsy 
  
History  No other medical history 
40% with family history of 
idiopathic epilepsy.  
Seizures Myoclonic jerks in all. 
GTCS in most. 
Absence seizure possible.  
Onset  80% between 12-18 years of 
age. 
Precipitating factors Sleep deprivation, alcohol 
intake, photic stimulation, 
fatigue, menstruation.  
Electroencephalograph  Irregular, fast poly-spike and 
waves on ictal and interictal 
EEG. 
Psychosocial symptoms  Mild-to-moderate 
psychopathological conditions 
possible, including: anxiety, 
depression and personality 
disorders. 
Treatment  85-90% responds to Sodium 
Valproate monotherapy. 
Respond to few other drugs 
and aggravated by others.  
Pharmacodependency  Relapse after drug withdrawal 
at any age. 
Prognosis Benign condition in most 
patients. 15% difficult to treat. 
                                                               Adapted from [69] 
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3.2 PREVALENCE AND INCIDENCE  
 
JME is a common epilepsy accounting for 26% of IGE cases, and with a prevalence of 
approximately 10% of all epilepsies [70]. However it has been estimated that due to the 
likelihood of JME being under diagnosed it may account for up to 30% of all epilepsy 
cases [1]. Table 3.2 below illustrates how since 1957 the prevalence has progressively 
increased. This trend is due to our increased understanding and awareness of JME, 
which has lead to it being more readily identified. Nevertheless the figure has not 
changed much since a report by GooBes in 1984 with studies since reporting 4-11% 
[69]. The prevalence of JME in the general population is 1 in a 1000 to 2000, equating 
to around 30,000-60,000 people in the UK diagnosed with JME [70]. The incidence of 
JME has been reported to be 1 in 100,000 population [9].  
 
 
Table 3.2 Number of cases, prevalence and sex distribution in patients with JME 
 
Study 
 
Patients (n) 
 
Prevalence % 
Ratio of 
males:females 
Janz et al (1957) 47 2.7 23:24 
Janz (1969)  280 4.3 149:131 
Gastaut et al (1973) 72 2.9  
Simonsen et al (1976) 37 2.8 21:14 
Tsuboi (1977) 399 5.4 195:204 
Van Heycop ten Ham (1981) 50 4.4 25:25 
Asconape and Penry (1984) 15 4.0 3:12 
GooBes (1984) 121 11.9 61:60 
Adapted from [65] 
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3.3 CLINICAL MANIFESTATIONS  
 
3.3.1 SEIZURES  
The onset of JME can occur between the ages of 6 and 22 years [9] with 80% of cases 
presenting between the ages 12 and 18 years [66]. The three seizure types are present 
at different ages with absences starting at a mean age of 11.5 years. Myoclonic seizures 
begin one to nine years later at a mean age of 15.4 years. Finally GTCS usually follow a 
few months after the onset of myoclonus at a mean age of 15.5 years [66]. Not all 
patients will present with all three seizure types, with reports of 12-54% of patients 
experiencing absences and 80-97% experiencing GTCS [9]. 
 
3.3.2 PRECIPITATING FACTORS  
Patients most commonly experience seizures on awakening and are often precipitated 
by sleep deprivation. The patient’s letter to Janz (excerpt above) went on to say how 
she would sleep late in an attempt to control her seizures, which were stimulated by 
lack of sleep, “So if I went to bed at midnight or one o’clock, say, it was impossible for me 
to get up at 7, 8 or 9 o’clock. If I did, then I started fidgeting like mad, and ended up with a 
seizure” [65]. A 5 year prospective study of 64 patients found 51 patients reported 
sleep deprivation in combination with another factor, lead to seizures [10]. Table 3.3 
below illustrates the precipitating factors patients reported in the Panayiotopoulos 
study. 
 
Another study reported that awakening (34%) was the most common precipitating 
factor, which was closely followed by sleep deprivation (28%) [14]. They also reported 
the following precipitating factors: fasting (15%), menstruation (32% of female 
patients), fever (14%), colourful lights (11%), unexpected sounds and alcohol (both 
2.8%). They found 80% of patients reported more than one precipitating factor [14].  
 
JME has one of the highest percentages of patients with photosensitivity with studies 
reporting the figure to be approximately 20-30% of patients with JME, with a slight 
female preponderance to photosensitivity [8, 37]. Patients report not only the classic 
‘flashing lights’ as a trigger but also fragmented sunlight shining through trees, and 
repeated patterns also known as pattern sensitive seizures. Photo- and pattern- 
sensitivity has been reported to cause both myoclonus and GTCS in JME patients [71]. 
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Table 3.3 Precipitating factors reported by patients with JME 
Factor Alone or in combination 
(%*) 
Sleep deprivation 89.9 
Fatigue 42 
Photosensitivity 21 
Television/video games 5 
Menstruation 7 
Concentration 13 
Stress, expectation, others 7 
None 4 
* Percentage of 64 patients                                                   Adapted from [10] 
 
 
3.3.3 ELECTROENCEPHALOGRAPH FINDINGS 
When Janz presented his review of JME he characterised the epileptic discharges as 
“bilaterally symmetric polyspike-wave complex(es), with fronto-central accentuation” 
[65]. This has been confirmed since by many [7-10, 12, 72]. The pattern usually 
presents with 5 to 20 generalised, often symmetrical, high frequency (10-16Hz) spikes, 
followed by lower frequency (2.5-5Hz) slow waves [9].  
 
The Interictal EEG of patients with JME shows a similar pattern with generalised spike-and-
wave and polyspike-and-wave complexes, but with a lower frequency of around 3-5Hz [9, 
12]. The background rhythms in patients with JME are often within normal limits with 
isolated complexes particularly around the frontal lobe [9, 65]. A case study of ten newly 
diagnosed adolescents found nine to have normal background rhythms. Six of the patients 
showed the characteristic poly-spike and wave complexes, while the remaining four showed 
a variety of poly-spike and/or wave complexes following hyperventilation [73].  
 
An interesting finding from the EEGs of JME patient’s is the dominant activity in the 
frontocentral region, with the ictal EEG showing the onset and highest voltage within 
this region [9, 11], and isolated complexes during interictal period often limited to the 
frontal region [65]. This has been suggested to result in neuropsychological deficits of 
the frontal lobes [11] and will be discussed in chapter four.  
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3.4 AETIOLOGY  
 
JME is an idiopathic epilepsy. Idiopathic comes from the Greek word idios meaning 
“one’s own” and pathos meaning “suffering”, and is used to describe a disease that has 
an unknown cause. However, although the exact cause of JME is unknown it is accepted 
to be an inherited disorder [66]. Entire families have been documented to have JME, 
indicating in these cases JME is an autosomal dominant disorder [8, 74]. In addition to 
these rarer cases, 40% of all JME patients have a 1st degree relative with another 
idiopathic epilepsy [69]. These findings suggest a strong genetic component to the 
disorder. Other researchers have documented focal abnormalities such as 
microdysgenesis in the frontal lobes [75] or neurochemical abnormalities [21, 22], and 
suggested these play a role in the phenotype of JME.     
 
3.4.1 STRUCTURAL ABNORMALITIES ASSOCIATED WITH JME 
Structural imaging data does not reveal any obvious pathological lesions or 
abnormalities in the brains of  JME patients, and it is rarely associated with prenatal or 
traumatic lesions [76]. However with advances in imaging techniques in the last decade 
there has been a plethora of research indicating structural brain abnormalities [75, 77-
79]. 
 
Volumetric MRI and voxel-based morphometry (VBM) are methods which have been 
essential in revealing abnormalities in the JME brain [79]. Tae et al reported an 
increase in frontal lobe volume in JME patients, which they suggest points to 
microdysgenesis [79]. Microdysgenesis is a term used to describe microscopic 
structural abnormalities [75]. This theory is supported by others, whom also 
speculated that microdysgenesis was the cause of the increase in grey matter volume in 
the mesial and basal frontal region that they found [20]. 
 
Two other independent studies have also found increased grey matter volume in the 
frontal cortex [75, 77], which may signify abnormalities in apoptosis during 
maturation. Apoptosis is a natural process, which prunes brain cells and occurs most 
frequently during childhood and adolescence. Thus, less apoptosis would lead to a 
higher volume of cells.  
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It is probable that these developmental disturbances are caused by genetic mutations 
[76]. Mutations in the EFHC1 gene have been found in JME, and linked to increased 
neuronal density and the formation of hyperexcitable circuits. This is due to 
interference of normal elimination of neurons during postnatal development [70]. 
However, Suzuki et al., found only 6 out of 44 families with JME had the EFHC1 
mutation [80]. Nevertheless inferences regarding the cognitive impairments found in 
JME have been attributed to these structural abnormalities [72].       
 
Other researchers have found abnormalities in the thalamus such as reductions in GMV 
and neuronal dysfunction [20, 81]. The findings of frontal and thalamic abnormalities 
lends support for the hypothesis that dysfunctions in the Thalamofrontal circuit is a 
major mechanism in JME [82]. The Thalamofrontal circuit projects from the anterior 
and medial thalamus to the dorsal-lateral prefrontal cortex (DLPFC). The DLPFC is an 
area which is highly associated with executive functioning [82, 83]. 
 
In addition to the frontal and thalamic abnormalities, researchers have reported wide 
spread anomalies in JME. One study reported structural and volumetric abnormalities 
in the frontal region, corpus callosum and hippocampus. This finding strengthens the 
argument that JME patients have an abnormal neural network, which is the cause of 
their symptoms [79].   
 
3.4.2 FUNCTIONAL ABNORMALITIES 
Research has not only found structural anomalies in the brains of JME patients, but also 
functional discrepancies [21, 22]. One study found abnormal cortical activation in 
patients with JME; reporting decreased activation during resting in the ventral 
premotor cortex, caudate, DLPFC and left medial premotor area [21]. These findings 
indicate widespread impairments in the frontal lobes. Moreover, during a visual 
working memory task, PET imaging revealed decreased activation in many regions of 
frontal locality particularly the DLPFC in JME patients [22].    
 
A study by Savic et al supports the above finding that patients with JME have 
abnormally low levels of activity in the frontal region. They reported significantly lower 
concentrations of N-acetyl aspartate (NAA) in the frontal lobes of JME patients when 
compared with controls using Magnetic Resonance Spectroscopy (MRS) [21]. This 
points to either neuronal loss or a general neuronal dysfunction; dysfunction in the 
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regulation of N-acetyl-L-aspartate aminohydrolase leading to the degradation of NAA; 
or a specific mitochondria dysfunction leading to less NAA being produced [21]. The 
researchers suggests that all of these possibilities could be explained by cortical 
dysplasia, despite not finding evidence for this themselves [21]. However the reason for 
this lack of evidence may be due to the dysplasia being microscopic, and thus too small 
to be imaged using MRI (i.e. microdysgenesis as discussed above). Researchers have 
also found decreased NAA levels in the thalamus of the JME brain [81].  
 
Further to classical volumetric MRI studies in JME, there have been recent applications 
of neuroimaging techniques assessing structural and functional connectivity in JME 
[84]. These approaches have shown altered thalamocortical and frontal connectivity 
alterations in patients compared to healthy controls [85-87], which may relate to 
functional connectivity alterations, and together may explain the cognitive triggering of 
motor seizures and frontal lobe cognitive impairments seen in patients with JME [87, 
88]. 
 
The findings above highlight that the structure, volume and activity of both the frontal 
cortex and thalamus are abnormal in the JME brain. It is clear from the evidence that 
these abnormalities are the likely aetiology of the JME phenotype; however the 
underlying cause of these abnormalities could be either sporadic or genetic. The 
evidence from family and genetic studies suggest in the majority of cases it is the latter. 
Below is a discussion of the possible genetic culprits.   
 
3.4.3 GENETICS  
Although findings of neurochemical imbalances and structural abnormalities are of 
great interest in understanding JME, and help provide an explanation for the cognitive 
and psychological symptoms experienced by patients, it does not explain how the 
anomalies came about in the first place. The evidence presented above suggested that 
developmental disturbances could be a consequence of genetic mutations e.g. in genes 
that encode for apoptosis. Unfortunately JME has high genetic heterogeneity [89] 
making the quest to find the culprit genes difficult.  
 
Thus far the majority of the genetic evidence from family studies have investigated 
linkage with many pointing to loci on Chromosome 6, in particular the region of the 
human leukocyte antigen (HLA) [90]. Strong evidence for this comes from independent 
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studies [74, 91, 92], all of which reported significant association between JME and HLA 
alleles. However, some studies have not found linkage to HLA in families with JME. 
While others have found evidence of susceptibility loci on Chromosome 15 [93]. More 
specifically, a gene (CHNRA7) that encodes for a receptor subunit (c7) of neuronal 
nicotinic acetylcholine that lies in region 15q14 [93]. In rare cases families have been 
found to have autosomal dominant JME. See Table 3.4 below for monogenic genes 
identified to date. 
 
 
Table 3.4 Monogenic genes identified in families with JME 
Genes  Reference  
GABRA1 Cossette et al (2002); Malijevic et al (2006) 
GABRD Dibbens et al (2004) 
CLCN2 Haug et al (2003) D’Agostino et al (2004) 
EFHC Suzuki etal (2004) 
                                                                                                       Adapted from [89] 
 
 
Twin data has revealed high concordance rates among monozygotic twins [76]. while 
family studies reveal many patients with JME have a first degree relative with another 
IGE or abnormal EEG recording, yet for some the disorder appears sporadic [94]. The 
above findings highlight the genetic heterogeneity of JME and indicate that although 
genetics play a strong influence in its aetiology, it is not a simple Mendelian disease 
[76], but is the result of a complex interaction of several genetic variations and 
environmental factors, which have yet to be fully elucidated [89]. 
 
Overall patients with JME are clinically very similar, but it is clear from the genetic 
heterogeneity that it is not a single disorder [72]. The current thesis aims to take the 
first step in describing one of the many probably subtypes of JME based on 
neuropsychological profile and personality. Future projects can then take the next step 
of identifying the genetic aetiology of this and other subtypes.   
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3.5 CO-MORBIDITIES   
 
3.5.1 MOOD 
Psychiatric disorders are often reported in Epilepsy with anxiety and depression being 
the most prevalent [95]. Researchers have found JME to be highly associated with 
mood disorders [27, 28, 96, 97]. One study found almost 50% of patients with JME in 
their sample also had a co-morbid mood or anxiety disorder [27].  
 
3.5.2 PERSONALITY  
Patients with JME are often reported to have distinct personality traits. Janz [65] first 
described them as “...immature and oscillates between friendliness and mistrust, a 
personality which tends to cause problems where social adaptation is concerned”. Studies 
that have investigated personality have found cluster B personality disorders 
(particularly borderline) significantly more in patients with JME than healthy controls 
[27, 98, 99]. Another study [97] reported the occurrence of personality disorders in 
patients with JME to be almost double the occurrence found in a study of the general 
population [100]. 
 
Investigators have suggested a link between these personality traits and executive 
dysfunctions reported in patients with JME [7, 11-13]. Additionally, researchers have 
described structural and functional abnormalities in the frontal lobes of JME [20-22], 
which have also been reported in patients with personality disorders [23, 24]. It may be 
postulated from these findings that the epilepsy and psychiatric disorders are 
symptoms of the same aetiology. This proposal is considered further in addition to a 
detailed discussion of frontal lobe dysfunctions in JME in Chapter four.       
 
3.6 TREATMENT  
 
3.6.1 AEDS 
The first line treatment for JME is monotherapy on VPA. It has been reported that 85-
90% of patients respond to it very well with most becoming seizure free [66]. However, 
for women of childbearing age treatment with VPA is not recommended due to its 
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association with developmental delay when in utero exposure occurs [57]. It is 
recommended that women are treated with one of the newer AEDs, such as LEV and 
LTG, which have been shown to be effective and safe for women with JME [101]. 
 
VPA has many additional adverse effects some of which are weight gain, sedation and 
liver problems, thus researchers have recently investigated the efficacy of LEV as a first 
line treatment for JME. Two independent studies both reported positive findings, 
indicating that LEV may be a better alternative to VPA, causing less adverse effects 
while still producing good seizure control [102, 103]. However, studies thus far into the 
uses of the newer AEDs for JME have not been adequately powered or randomised 
[104]. Therefore conclusions must be drawn with caution.   
 
Many patients who do not respond to monotherapy have shown promise on 
polytherapy, which is when a patient is on more than one drug usually VPA plus 
another agent [66]. Table 3.5 lists the current pharmacological treatments used for 
JME.  
 
All other current AEDs have not been found to be successful in treating JME, with 
Phenytoin and Carbamazepine aggravating myoclonic and absence seizures [66]. 
Although drug therapy is very successful in JME, seizures return if medication is 
withdrawn [37], thus it is necessary to continue treatment for life.       
 
 
Table 3.5 Pharmacological treatment for JME 
First line treatment  Second line treatment 
Sodium Valproate Levetiracetam 
 Lamotrigine 
 Topiramate  
 Clonazepam  
 Primidone  
  Acetazolamide  
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3.7 PROGNOSIS 
 
The overall prognosis for patients with JME is positive with it becoming a benign 
disorder for most on appropriate treatment [66]. Over 70% of patients have controlled 
seizures many of which are on VPA monotherapy. Nonetheless JME is considered a 
lifelong disorder, since relapse rate is high following discontinuation of treatment. This 
is even the case for patients who have been seizure free for many years. One study 
reported a relapse rate of 90% after medication was withdrawn [105]. Thus it is 
recommended that medication is maintained for life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
CHAPTER FOUR – PATTERN AND CAUSES OF 
NEUROPSYCHOLOGICAL DYSFUNCTIONS IN JME 
 
 
A pattern of impairment in JME has been identified, with many finding the greatest 
impairments in verbal memory [12, 13] and executive functions [7, 11-13]. This 
chapter will discuss the pattern of dysfunction that previous research has found. A 
discussion of the possible causes of these impairments will then be given.  
 
4.1 PATTERN OF NEUROPSYCHOLOGICAL IMPAIRMENT 
 
Focal epilepsies have long been linked with cognitive deficits [13]. However in the last 
20-30 years researchers have shifted their attention to cognitive deficits in idiopathic 
epilepsies. Idiopathic epilepsies have no clear detriment to the brain and unknown 
pathologies. Thus, to gain a better understanding of the underlying aetiology, the 
causes of cognitive deficits need to be elucidated. JME is one IGE that has received 
attention, particularly in the last decade.  
 
4.1.1 FRONTAL LOBE AND EXECUTIVE FUNCTIONS 
Executive functions are complex cognitive processes that generate cognitive and 
behavioural responses, and strategies to achieve immediate or future goals [106]. 
Executive functions are highly associated with the frontal lobes [105]. 
 
The most consistent impairment that has been found in JME is frontal lobe dysfunction. 
Devinsky et al found patients with JME had impairments of several executive functions 
associated with the frontal lobe [11]. These included concept formation, mental 
flexibility, planning, and cognitive speed. Similar findings have been reported by others  
 [7, 12-14, 16, 22, 72, 107]. One study reported that JME patients performed worse than 
normal controls across a neuropsychological battery, which reached significance for 
verbal fluency (p = 0.030), and semantic fluency (p = 0.012) [72]. Another study 
compared JME patients with patients with frontal lobe epilepsy (FLE), temporal lobe 
epilepsy (TLE) and controls [12]. They found the JME group performed significantly 
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worse than TLE (p< .001) and normal controls (p< .001) on the Wisconsin card sorting 
test (WCST; an executive function test that assesses planning, mental flexibility, 
concept formation, and strategy formation) and verbal fluency. In addition they found 
the performance of the JME group did not significantly differ from the FLE group 
(p<.05), providing strong support for frontal lobe involvement in the cognitive 
problems associated with JME.  
 
Although the studies above have all found executive dysfunctions they have often 
differed in the pattern of impairment. It has been reported that impairments in word 
fluency and interference were the most consistent finding in JME [16]. Word fluency is 
the ability to quickly generate words beginning with a specified letter of the alphabet or 
words in a given semantic category. Interference is the ability to inhibit an over learned 
verbal response in order to generate a conflicting response. Following a review of the 
literature it was revealed that all studies that measured word fluency and/or inhibition 
found patients with JME were impaired. Table 4.1 below briefly outlines the methods 
and findings of these studies. 
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Table 4.1 Studies showing impairments in verbal fluency and/or inhibition in patients 
with JME 
Study Participants 
Cognitive 
domains  Results 
Pascalicchio et 
al (2007) [13] 
50 patients with 
JME, >17 years of 
age and 50 
healthy controls 
matched on age, 
gender and 
education.  
Intellect, memory, 
language and 
fluency, attention 
and executive 
functioning 
JME group scored sig 
lower on attention, 
immediate verbal 
memory, mental 
flexibility, control of 
inhibition, working 
memory, processing 
speed, verbal and visual 
delayed memory, naming 
and verbal fluency.  
Iqbal et al 
(2009) [7] 
8 JME patients, 
8 unaffected 
siblings and 16 
healthy controls 
matched on 
gender, age, 
ethnicity and 
education.   
Intellect, memory, 
language, fluency, 
attention, 
executive 
functioning, and 
visuospatial 
ability.    
 JME group scored lower 
on verbal and executive 
functioning tasks than 
their sibling’s and 
controls, but this only 
reached significance for 
the controls.   
 
Sonmez et al 
(2004) [14] 
35 patients with 
JME, >16 years of 
age and 35 
healthy controls 
matched on age, 
gender and 
education. 
Intellect, memory 
and learning, 
complex 
perceptual and 
construction 
ability, attention, 
language and 
executive 
functions. 
 The JME group’s total 
learning score was sig 
lower than controls. 
They also scored sig 
lower on memory and 
executive functions. 
Piazzini et al 
(2008) [12] 
50 patients with 
JME, 40 with FLE, 
40 with TLE and 
40 healthy 
controls matched 
on age, gender, 
education and IQ. 
Intellect and 
executive 
functions. 
JME and FLE patients had 
significant impairments 
on executive functioning 
compared to TLE 
patients and controls.  
Linear regression 
analysis for the JME 
group showed the 
duration of epilepsy, 
seizure frequency, 
treatment and seizure 
type where not 
associated with 
neuropsychological 
impairments. 
Devinsky et al 
(1997)[11] 
 
15 patients with 
JME and 16 with 
TLE matched on 
IQ, age, age of 
onset and 
duration of 
epilepsy. 
Executive 
functions and 
intellect  
JME patients showed 
impairments in concept 
formation, mental 
flexibility, cognitive 
speed, planning and 
organisation. JME had sig 
lower scores on the 
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WCST and trail making 
test. 
De Toffol et al 
(1997) [107] 
9 JME and 9 
healthy controls 
matched on age, 
gender, education 
and handedness 
Executive 
functions, verbal 
fluency and 
Stroop. 
JME patients were 
significantly more 
impaired on all of the 
tests, indicating deficits 
in planning, fluency and 
inhibition (executive 
functions). 
Swartz et al 
(1996) [22] 
9 JME and 14 
healthy controls 
matched on age, 
education and 
handedness 
 
Immediate and 
delayed memory. 
 
There was no sig 
difference between JME 
and control subjects on 
the IMS task, indicating 
both groups had normal 
attention. The DMS task 
revealed the JME group 
to have impaired visual 
working memory. 
Wandschneider 
et al (2010) 
[16] 
19 JME, 21 
unaffected 
siblings and 21 
healthy matched 
controls 
Intellect, memory, 
executive 
functions, and 
prospective 
memory.  
The JME group 
performed sig worse 
across all neuropsych 
tests compared to 
controls. The PM task 
revealed JME group were 
impaired on intention 
formation, completing 
tasks and sticking to 
rules.  
Roebling et al 
(2009) [72] 
19 JME and 20 
age-, sex- and 
education-
matched controls 
Intellect, memory 
and executive 
functions. 
JME group performed 
worse across all tests 
with the difference 
reaching sig on verbal 
and semantic fluency.  
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4.1.2 MEMORY  
Past research has found memory impairments in people with JME, particularly verbal 
memory and/or visual memory [13, 14, 16]. One study found JME patients scored 
significantly lower on tests of immediate (p= .017) and delayed verbal memory (p= 
.013), and delayed visual memory (p= .014) compared to healthy gender, age and 
education matched controls [13].  
 
There could be several causes of these impairments, some of which include AED 
treatment, seizure type, and frontal lobe abnormalities. Support for frontal lobe 
abnormalities being a cause of the memory impairments found, comes from a study by 
Swartz et al [22]. They reported that JME patients have a significant deficit in visual 
working memory compared to healthy matched controls. Moreover, with the use of PET 
they found significantly less uptake of 18-fluorodeoxyglucose (18FDG) in the frontal 
cortex compared to controls during a visual working memory task. In addition, unlike 
controls the PET scans of the JME patients showed activation in the medial temporal 
cortex during the task [22]. The authors of this study and others suggest that these 
findings may indicate a disorder of neuronal migration and cortical disorganisation, 
both of which may play a role in the impairments found and epileptogenic symptoms of 
JME [12, 22, 108]. All the possible causes of memory impairments in JME will be 
discussed in detail below in the second half of this chapter. 
 
4.1.3 PERSONALITY  
Impaired inhibition and fluidity of thought are highly associated with personality 
disorders, and it has been suggested that the low performance on these tasks is related 
to the personality traits exhibited by people with JME [16]. People with JME have often 
been found to have distinct personality traits [27, 98, 99]. Janz and Christian described 
people with JME as emotionally unstable and immature, unsteady, lacking discipline, 
hedonistic, having frequent and rapid mood changes, and indifferent to their disease 
[65].  
 
Similar traits have been found more recently. One study comparing people with JME 
with healthy matched controls found 20% of the JME group (significantly more than the 
controls p = .008) were classified with personality disorders, displaying similar traits as 
described by Janz [27]. Another study compared personality disorders in JME with 
structural prefrontal brain abnormalities using voxel-based morphometry [20]. They 
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reported a significant reduction in grey matter volume in JME patients compared to 
healthy controls. This reduction was found in the insula (p= .006), thalamus (p= .001) 
and cerebellum (p= .006), and a decrease in white matter volume in the cerebellum (p= 
.03) was also reported. In addition they found increase grey matter volume in the right 
superior and medial frontal gyri (p< .001 and p= .001, respectively). Differences in 
brain volume were also found when the JME patients with PD were compared to JME 
patients without PD. The patients with PD had significantly less grey matter volume in 
the right thalamus than patients without (p< .001). In addition the patients with PD had 
increased volume in the left and right middle frontal gyri (p< .002 and p< .001, 
respectively), and the right orbitalfrontal gyrus (p< .004).   
 
The findings reported by de Araujo et al [26, 27] indicate a relationship between JME 
and structural brain abnormalities, particularly in patients with PD. As of yet no 
investigation has been conducted that correlates frontal impairments and personality 
disorders [16, 27]. The current study will examine both frontal dysfunctions and 
personality disorders in order to determine whether a relationship exists between 
them. 
 
4.1.4 MOOD 
Co-morbid mood disorders are often found in people with JME. A study described 
above [27] found that almost half (49 of 100) of the participants with JME also had a 
mood or anxiety disorder. Another study reported that JME patients scored 1.5 
standard deviations above their siblings and healthy matched controls for depression 
on the HADS [7]. Additionally the JME patients and their siblings scored 1 standard 
deviation above the healthy controls for anxiety.  
 
It is well established that there is a relationship between mood and cognitive 
functioning [109]. Studies have reported that depressed individuals perform 
significantly worse than healthy controls on recall and acquisition [110, 111]. One 
study found depressed individuals had significantly impaired immediate recall and 
acquired significantly less information than individuals with low levels of depression. 
In addition, they found when anxiety co-exists not only are the above findings found, 
but participants also retrieved significantly less newly learned information after a 20 
minute delay [112].  
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It has been suggested that negative mood can exacerbate memory problems in people 
with epilepsy [113]. However this relationship has rarely been examined in patients 
with JME. Considering the high percentage of JME patients with mood disorders it is 
important to investigate whether mood has an impact on the cognitive impairments 
found in these patients. 
 
4.2 POSSIBLE CAUSES OF COGNITIVE IMPAIRMENTS  
 
JME has been associated with cognitive deficits since Janz and Christian description in 
1957, yet in the majority of cases patients maintain intellectual functioning that is 
within normal limits [7, 13, 72]. Despite this many researchers have found impairments 
in cognition [7, 11-14, 16, 22, 72, 107], and one recent study reported that JME amongst 
other IGE patients had significant cognitive impairments at time of diagnosis and 
before the onset of treatment [114].    
 
Moreover, patient’s unaffected siblings have also been found to be more impaired than 
healthy unrelated controls across a wide range of neuropsychological assessments [7]. 
These findings suggest an underlying physiological dysfunction in the brain. The latest 
research has suggested dysfunctions in the fronto-thalamo circuit [82], this however is 
beyond the scope of the current thesis. For an overview of this hypothesis please see 
[115]. What is clear from past research is that the cognitive deficits in JME are multi 
factorial. Table 4.2 gives the possible contributory factors, which will be discussed in 
detail for the remainder of this chapter.  
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Table 4.2 Factors that may influence cognitive functioning in JME  
Contributory factor  
Pathophysiology Underlying brain abnormalities, focus of 
epileptogenic activity 
Epilepsy onset and duration Age of onset and duration 
Seizure related Type, frequency, interictal activity and 
severity 
Treatment related AEDs, dose, drug interactions 
Psychosocial related Mood (depression and anxiety), 
personality traits, stigma, self-esteem, 
education/occupational attainment   
 
 
 
4.2.1 BRAIN IMAGING AND COGNITION 
As discussed in detail in chapter three, patients with JME have been found to have 
increased frontal grey matter volume [75, 77]. The researchers of these findings have 
suggested that the increased volume is caused by a malfunction in normal 
developmental neuronal pruning (apoptosis), and thus leads to inefficient and/or 
abnormal functioning of the frontal lobes. Indeed, reduced activity in the frontal lobes 
of JME patients has been reported [21]. Decreased GMV and low activity in the 
thalamus has also been reported in JME [20, 21, 81] 
 
The structural and functional brain abnormalities in JME has been investigated by 
numerous researchers [21, 22, 72, 75, 77, 79, 81, 116-118]. While several others have 
investigated the cognitive impairments [7, 11-14, 16, 65, 72]. Many of these researchers 
have speculated that the two are correlated, yet there has only been one study that has 
investigated both cognition and brain structure to the best of the author’s knowledge. 
 
One study found compared to healthy matched controls, patients with JME had 
significantly smaller right thalami (p= .02), and more frontal CSF (p = .001) indicating 
smaller frontal cerebral volume [82]. JME patients also had more frontal CSF (p= .007) 
than patients with Benign childhood epilepsy with centrotemporal spikes (BCECTS) 
who formed an active control group. In terms of cognition JME were significantly 
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impaired on inhibition (p= .01), and behavioural regulation (p= .03) when compared to 
healthy controls [82] 
 
When Pulsipher et al.,  investigated the relationship between the volume abnormalities 
and cognition, they found that frontal tissue and thalamic volume were the only, and 
significant predictors of JME patients performance on the D-KEFS [82]. Specifically, 
frontal grey matter volume (GMV) and white matter volume (WMV) explained 57% 
(adjusted r²) of the variance in category switching accuracy from the DKEFS. The 
standardised beta values indicated that frontal grey matter was negatively correlated, 
thus high GMV is associated with low ability to accurately switch between two 
unrelated categories (β= -2.04). Conversely, frontal white matter was positively 
correlated with category switching accuracy, thus decreases in WMV in the frontal lobe 
is associated with poor performance (β= 2.17). Similarly, a decrease in WMV (β= 1.38) 
explained 13% (adjusted r²) of the variance in inhibition. Lastly, right and left thalami 
volume explained 39% of the variance found in performance on the card sorting test 
from the DKEFS. Left thalami was positively (β= 1.62), and right thalami was negatively 
(β= -1.54) correlated with card sorting. Therefore, increased left thalami volume is 
associated with poor ability to sort cards into categories, while decreased right thalami 
volume is associated with poor ability of this task.       
 
This study directly correlated cognition with brain abnormalities, and gives strong 
support for executive dysfunctions being a symptom of the syndrome. The current 
thesis hope to lend support to this report by demonstrating that most of the other 
factors (in the Table 4.2 above) contribute little to the known neuropsychological 
profile in JME.  
 
4.2.2 EPILEPSY ONSET AND DURATION  
JME is a lifelong syndrome that begins in adolescence [8], thus the contribution that age 
of onset and duration of epilepsy play in cognitive impairments will be investigated in 
the current thesis. Studies of epilepsies that begin in childhood have revealed a 
negative impact of the age of onset on socioeducational development, often resulting in 
lower cognitive abilities, job prospects and quality of life [119]. This has rarely been 
documented in JME patients. Sonmez et al found no correlation between age of onset 
and cognitive impairments in patients with JME [14].  
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The findings on the impact of the duration of the disease are mixed. One study that has 
investigated the neuropsychological profile of JME patients, found they were 
significantly impaired across most neuropsychological assessments compared to 
healthy matched controls, and that this impairment was correlated with the duration of 
the disease [13]. However, this finding was not replicated in a study by Sonmez et al, or 
in a study by Piazzini et al, who both reported no correlation between cognition and 
duration of JME [12, 14].    
 
4.2.3 SEIZURE RELATED  
Seizures are sudden violent bursts of electrical discharges that focus in one region or 
the entire cortex of the brain, thus it is reasonable to hypothesise they may have a 
deleterious effect on cognition. Much research has been done over the last 30 years in 
order to determine whether seizures cause impairments in cognition in PWE [119-
121]. Following a review of the literature it was concluded that uncontrolled seizures 
lead to decreased mental ability in PWE [119]. In addition, GTCS have been significantly 
associated with cognitive impairments, this is particularly true for prolonged GTCS i.e. 
convulsive status epilepticus [119]. 
 
Little research has been conducted that has examined the contribution seizures play in 
the known neuropsychological impairments in JME. Sonmez et al concluded from past 
research that when seizure control is achieved IQ levels are not changed. However the 
opposite is true for patients with multiple seizure types, and frequent and long lasting 
seizures [14]. However, these patients may have worse brain abnormalities, which 
result in poor seizure control and cognitive impairments. In Sonmez et al.’s own study 
they did not find an association between IQ and seizures [14].   
 
The majority of JME patients have normal IQ, but have impairments in executive 
functions, thus one investigated the contribution seizure play in these impairments 
[12]. They found JME patients were significantly impaired on frontal lobe tests, 
compared to patients with TLE and healthy controls. Yet there was no association 
between these frontal lobe impairments, and the frequency or type of seizures. This 
suggests that seizures are not a key contributory factor. 
 
Another factor that may have a greater impact and is related to seizures is interictal 
discharges. JME patients are characterised by abnormal EEG with the majority of the 
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activity in the frontal regions [11, 96, 122]. Although little research has revealed any 
significant effects of seizures on cognition in JME patients, associations have been 
found with abnormal interictal activity. A study by Lavandier et al reported that JME 
patients with interictal epileptiform EEG activity were more impaired on some frontal 
tasks, than JME patients without discharges [12]. Another study found more errors 
were made on the Stroop test (a test that assesses inhibition that is controlled by the 
frontal lobe) by JME patients who had paroxysmal EEGs compared to patients who had 
normal EEGs [14]. 
 
However a study that used video-EEG recording during a neuropsychological 
assessment found no increase in discharges, which the authors hypothesised, would 
explain the impairments found. They concluded that the neuropsychological 
impairments observed in the JME patients were independent of abnormal discharges 
[7]. Yet Iqbal et al. did find in the one patient in their study that did experience 
discharges at the point of learning, could not recall the information that directly 
corresponded to the discharge.    
 
The mere fact of having seizures and/or paroxysmal interictal discharges, and the type 
of seizures experienced by JME patients may contribute to the neuropsychological 
impairment. Sonmez et al reported patients whom experience both myoclonic seizures 
and absences scored worse on tests of short term memory. In addition visual memory 
and recall were impaired in patients with absence seizures [14]. More recently, 
however a study by Piazzini et al found no association between the type of seizures JME 
patients experience, and the significant impairment in frontal functions they reported 
[12].  
  
The research thus far does not indicate any clear association between cognitive 
impairment in JME and having seizures. Additionally the findings regarding the impact 
particular types of seizures have, are contradictory. What is clearer however is the 
presence of paroxysmal discharges during rest and executive dysfunctions. 
Interestingly, one study found EEG abnormalities in the frontal region were 
significantly associated with experiencing both GTCS and myoclonic seizures, a family 
history of epilepsy and being refractory to AED treatment [123].  
 
Moreover, a study that compared VPA resistant JME patients to VPA sensitive patients 
found the refractory patients had abnormal EEGs with frontal predominance and left 
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temporal slowing. They suggested that the VPA sensitive patients resembled the JME 
syndrome described by Janz [65], while the refractory patients were a distinct 
subgroup of JME or possibly a different type of epilepsy altogether [124]. This suggests 
that it is the refractory patients that still experience paroxysmal discharges who suffer 
with frontal lobe impairments. This highlights the multifactorial and heterogenic 
nature of this syndrome.  
 
4.2.4 TREATMENT RELATED 
There is much debate over the impact AED’s have on cognition with many patients 
attributing their impairments to their medication [114]. A review of the literature 
reported that psychomotor speed, vigilance, memory, attention and mood are affected 
by AEDs [125]. However, the studies cited in the review by Hirsch et al were conducted 
with patients who had been diagnosed with epilepsy for many years, thus the cognitive 
impairments reported may be a result of years of recurrent seizures. However, a study 
by Taylor et al investigated the cognitive profiles of PWE before the commencement 
AED treatment [114]. They reported PWE were significantly impaired on over half of 
the test battery with the difference in memory and psychomotor speed remaining 
significant once sex, age and education were controlled for. This suggests that much of 
the cognitive impairments reported in epilepsy are not due to AEDs.  
 
However no such study has been conducted solely with JME patients. Furthermore, due 
to the heterogeneity of JME, and differing responses to treatment it remains unclear 
whether some of the cognitive impairments described in JME patients are due to 
antiepileptic drug treatment. One study conducted compared JME patients with healthy 
age, sex and education matched controls [72]. They reported JME patients performed 
slightly worse on most neuropsychological tests including those of working memory, 
episodic memory, verbal and semantic fluency, attention, inhibition and vocabulary. 
The difference in performance reached significance for verbal and semantic fluency. 
However, both verbal and semantic fluency are associated with the functioning of the 
frontal lobes [12], and many suggest frontal lobe impairments are indicative of the 
underlining aetiology of JME.  
 
A key factor that needs to be considered is the difference between AEDs, as a review by 
Meador et al demonstrated that particular AEDs have been found to be more 
detrimental to cognition than other AEDs [126]; Figure 4.1 below summaries their 
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findings. More recently a study investigated the difference between the first line 
treatment for JME (Valproate) with another effective JME AED (Lamotrigine) [71]. They 
found JME patients treated with VPA scored worse on most tests compared to those 
treated with LTG or no medication, and performed significantly worse on verbal 
memory [72]. However, another review of the literature reported that at therapeutic 
doses, VPA causes either mild or no cognitive impairments [127].  
 
 
 
 
 
 
 
 
 
 
 
(Adapted from [126]) 
Fig 4.1 Relative cognitive effects of AEDs  
 
 
It is clear that AEDs (some more than others) have an effect on cognition, with some 
studies showing significant impairments while others show no impairments. The exact 
extent they contribute to the cognitive impairments documented in JME has not been 
elucidated to date, and thus it remains an important question to tackle. However, one 
must not forget that seizure control significantly improves a patient’s quality of life, 
thus may be deemed as more important than mild adverse effects of AEDs.   
 
4.2.5 PSYCHOSOCIAL RELATED 
 
 
4.2.5.1 Mood and personality  
Mood and personality disorders are extremely common in JME. One study reported that 
almost 50% of JME patients in their sample also had a co-morbid mood disorder and/or 
anxiety disorder [27]. Mood disorders, particularly depression are correlated with 
cognitive impairment in healthy and clinical populations [112]. Thus the high co-
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morbidity of mood disorders in JME may play a key role in the reported cognitive 
impairments.  
 
In the same study by de Araujo et al. they reported 20% of their JME sample were 
classified as borderline, and exhibited the distinct personality traits that were first 
described by Janz [65], and by many since [9, 27, 98, 99]. Another study [97] reported 
the occurrence of personality disorders in patients with JME to be almost double that 
found in a study of the general population [100]. 
 
People with personality disorders such as borderline personality, have been found to 
have impairments in planning and inhibitions [18, 19] synonymous to the impairments 
found in JME patients. Furthermore, these same impairments are also found in patients 
with frontal lobe epilepsy (FLE) whom have a focal lesion in the frontal lobes [12]. 
Piazzini et al found when compared to healthy controls and patients with temporal lobe 
epilepsy (TLE), JME and FLE patients were significantly impaired on the WCST. 
However, when the performance of JME and FLE patients was compared no significant 
differences were found, supporting the hypotheses that JME patients have focal 
abnormalities in the frontal lobes.  
 
The current thesis aims to investigate the relationship between the executive 
dysfunctions in JME, and personality disorders to explore whether low executive 
functions accounts for the personality traits or vice versa. Additionally this thesis aims 
to examine whether there are JME patients whom have low executive functions, but 
normal personality. This would provide evidence for an underlying pathological 
abnormality in the frontal lobes of JME, or personality traits purely being a symptom of 
a subtype of JME.   
 
4.2.5.2 Education 
Another factor that may impact cognition in JME patients is level of education. A study 
by Pascalicchio et al found significant impairments across several of the tests 
administered, and a positive correlation between duration of epilepsy and cognitive 
decline. Yet this significant correlation was lost if patients had, had more than 11 years 
of formal schooling and remained strong if patients had spent less than 11 years in 
education [13]. This indicates that education compensates for years of seizures.  
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4.3 CHAPTER FOUR SUMMARY 
 
The current chapter has reviewed the literature that has investigated the 
neuropsychological profile of JME. The literature indicates that patients with JME for 
the most part maintain an IQ that is within normal limits [7, 13, 72]. Despite this, 
people with JME have been repeatedly found to have impairments in executive 
functions, particularly inhibition and verbal fluency [7, 12-14, 16, 22, 72, 107]. In 
addition to these impairments some researchers have reported deficits in memory [13, 
14, 16], abnormal personalities [27, 98, 99], and mood disorders [27].  
 
The literature discussed above clearly indicates that JME is a complex heterogeneous 
disorder, and although it is one of the most common forms of epilepsy little is still 
understood about its cause. One approach to gaining a better understanding of the 
underlying aetiology, and providing better treatment plans for patients is by 
determining what causes or contributes to the cognitive impairments reported in JME.   
 
The latter half of this chapter proceeded in discussing the possible factors that may 
contribute to the reported impairments and abnormalities.  All of these factors will be 
investigated in the current thesis; however there will be a particular focus on the 
contribution of personality and frontal lobe involvement.   
 
 
 
 
 
 
 
 
 
63 
 
CHAPTER FIVE – AIMS AND HYPOTHESES 
 
 
5.1 AIMS AND OBJECTIVES OF THE CURRENT THESIS 
 
It has been hypothesised that JME is not one disorder but several, encompassing 
different aetiologies, yet indistinguishable epileptic symptoms. Hence the current thesis 
aims to examine the relationship between the executive dysfunctions in JME and 
personality, and investigate whether patients with abnormal personality traits present 
with worse executive dysfunctions.     
 
 
The objectives of the current thesis are to: 
 
1. Verify the neuropsychological profile of JME. 
2. Examine the contribution of age of onset, duration of epilepsy, education, type 
of seizures, seizure frequency, treatment, mood, impact of epilepsy and 
subjective view of cognitive functioning.   
3. Examine the impact of high levels of anxiety and/or depression on 
neuropsychological functioning in a refractory JME sample. 
4. Examine the relationship between personality and executive dysfunctions. Aim 
to provide evidence for frontal lobe involvement, and for the hypothesis that 
there is more than one type of JME.  
The hypotheses of the current thesis will be given below, along with a brief discussion 
of the research that led to them.  
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5.2 HYPOTHESIS ONE – NEUROPSYCHOLOGICAL PROFILE  
 
Chapter four discussed in detail past research that has investigated the 
neuropsychological profile of JME.  From this review of the literature it was concluded 
that the most consistent deficits found in JME are impairments in inhibition and verbal 
fluency, both of which are executive functions and associated with the frontal lobes 
[128]. The current thesis aims to confirm these impairments.  
 
It is thus hypothesised that the participants whom are drug-refractory will be 
significantly impaired on inhibition and verbal fluency. Secondly, as the patient group 
investigated in the current thesis consists of only refractory patients it is hypothesised 
that other cognitive impairments will be revealed.   
 
5.3 HYPOTHESIS TWO – OTHER CONTRIBUTORY FACTORS  
 
Although the current thesis has hypothesised that personality plays a key role in the 
executive dysfunctions in JME, other factors cannot be ignored. Especially as not all JME 
patients have an abnormal personality, and studies that have examined non-refractory 
and refractory patients as one group have still found significant impairments. 
Therefore, there must be other factors contributing to these impairments.  
 
The current thesis aims to examine the impact the following factors have on the 
neuropsychological impairments:   
 
5.3.1 AGE OF ONSET  
Age of onset has been found to impact cognition in epilepsy patients in general, with 
studies reporting early onset having a negative impact on cognition [119]. However, 
another study did not find this to be the case in JME [14]. Thus the present thesis will 
investigate this with the current sample.  
5.3.2 DURATION OF EPILEPSY 
The findings on the impact of duration of epilepsy in JME have been inconsistent. One 
controlled study investigating the neuropsychological profile of JME found that the 
significant impairments found in JME compared to healthy matched controls were 
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correlated with the duration of epilepsy [13]. However, this finding was not replicated 
by two other independent controlled studies [12, 14]. The current thesis will 
investigate the impact of the duration of epilepsy with the current sample.  
5.3.3 TYPE OF SEIZURES 
JME is associated with myoclonus, GTCS and Absences. It has been reported that 
impairments in short term memory is associated with experiencing both myoclonus 
and absences [14]. This finding has not be consistently reported in JME [12], and is 
unlike the findings for epilepsy in general, for which GTCS are associated with cognitive 
impairments. However, the current sample consists of only refractory patients, many of 
whom experience myoclonus and/or absences daily. Reasonably it would not be 
unexpected to find this level of seizure activity negatively impacting cognition. Thus the 
current thesis aims to investigate the impact of seizure type.  
5.3.4 TREATMENT  
Research to date indicates that some AEDs may be related to significant impairments in 
cognition. However, with regards to JME patients there has been no study that has 
exclusively investigated the effects of AEDs, and thus it remains an important question 
to tackle. Therefore, the current thesis will examine the contribution the AEDs 
prescribed to the current sample have on cognition.   
5.3.5EDUCATION  
Past research suggests that years of education and/or level of education has a positive 
impact on neuropsychological test scores [12], and may compensate for years of 
seizures [13]. The current thesis aims to investigate the contribution years and the 
levels of education have on the cognition of the current sample. Years of education will 
also be controlled for when investigating the first hypothesis.  
 
5.4 HYPOTHESIS THREE – PSYCHIATRIC SYMPTOMS AND 
NEUROPSYCHOLOGICAL FUNCTIONING  
 
Mood disorders have been correlated with cognitive impairments in healthy and 
clinical populations [112]. Mood  and anxiety disorders have been reported highly in 
JME, with one study reporting 50% of their sampling being classified with a mood 
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disorder [27]. Thus it is important to investigate the impact the high co-morbidity of 
mood disorders has on the cognitive impairments reported.    
 
5.5 HYPOTHESIS FOUR – PERSONALITY AND EXECUTIVE 
FUNCTIONS 
 
Abnormal personality traits have been repeatedly reported in studies of JME [9, 27, 65, 
98, 99]. The personality traits reported are synonymous to those described in 
borderline personality disorder [18, 19], and one JME study reported a high percentage 
of JME patients were classified as borderline [27]. Moreover, borderline personality 
disorder is associated with executive dysfunctions. Finally, the executive dysfunctions 
found in JME are similar to those found in frontal lobe epilepsy, which is a focal 
epileptic disorder.  It therefore follows that the personality traits in JME may be related 
to the executive dysfunctions, and the personality traits may be a result of an 
underlying frontal lobe abnormality. 
 
As of yet no investigation has been conducted that correlates frontal dysfunctions and 
specific personality traits in drug-refractory JME [16, 27]. It has been hypothesised that 
JME is not one disorder but several, encompassing different aetiologies, yet 
indistinguishable epileptic symptoms. Hence the current thesis aims to examine the 
relationship between the executive dysfunctions in JME and personality traits, and 
investigate whether patients with abnormal personality traits have a different type of 
JME to those with normal personality traits 
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5.6 SUMMARY OF CHAPTER FIVE 
 
The current thesis has four main hypotheses, which will be investigated: 
1. The refractory JME sample will be significantly impaired on inhibition and 
verbal fluency.  
2. Clinical characteristics and mood will have an impact on any cognitive 
impairments found in the refractory JME sample. 
3. Refractory JME patients with high levels of anxiety and/or depression will be 
more impaired on neuropsychological functioning than those with normal 
levels of anxiety and/or depression 
4. Participants with abnormal personality traits as determined by the EPQ-BV will 
be more impaired on executive functions than participants with normal 
personality traits 
 
Details of how the aims and hypothesis of the current thesis will be investigated will be 
given in detail in Chapter six.  
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CHAPTER SIX – DESIGN AND METHODS 
 
6.1 OVERVIEW OF THE CHAPTER 
This chapter will outline the methodology used to investigate the neuropsychological 
profile of patients with refractory JME. The methodology was designed to investigate 
refractory JME patients, and assess whether JME patients with abnormal personalities 
are more impaired on executive functions and cognition than JME patients with a 
personality profile within normal limits. In addition, the methodology was designed to 
assess the impact of the following factors: 
i. Seizure type and frequency 
ii. AEDs  
iii. Age of epilepsy onset 
iv. Family history of epilepsy 
v. History of febrile seizures 
vi. Age  
vii. Years in education 
 
 The design, participants and procedure of the current thesis will be given in this 
chapter and split into the following sections:  
1. General methodology 
2. Recruitment and description of participants  
3. Neuropsychological tools utilised  
4. Procedure  
5. An outline of the statistical analysis conducted 
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6.2 GENERAL METHODOLOGY 
 
6.2.1 RECAP OF AIMS AND HYPOTHESIS  
The main aim of the current thesis is to investigate the relationship between the 
reported neuropsychological deficits in patients with JME, and the abnormal 
personality traits these patients are described to have. Additionally, the aim is to assess 
the impact of the contributory factors listed above and discussed in detail in Chapter 
four. Finally, the current thesis aims to examine the neuropsychological, social and 
clinical profile of JME patients who do not respond on AED treatment [13]. 
 
6.2.2 CONTRIBUTION OF THE THESIS AUTHOR J.W. 
18 participants were collected by research assistants at the University of Liverpool as 
part of the MRC funded ReJuMEC study. A further 21 participants were recruited and 
assessed by Dr Rhys Thomas as part of Wales Epilepsy Study. The author, J.W 
conducted 21 assessments, and arranged and confirmed each by letter and telephone. 
The author spent 62 hours conducting testing face to face, 51 hours of scoring and 16 
hours of preparing feedback. J.W travelled a total of 2416.8 miles to carry out the 
assessments, equating to an average of 115 miles per assessment. This constitutes an 
average of 2.5 hours of travelling per participant and 48 hours spent travelling overall. 
In addition, J.W. arranged travel and accommodation required for the long distance 
assessments.      
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Fig. 6.1 Number of neuropsychological assessments conducted across the UK by the 
author J.W 
 
 
6.2.3 ETHICS 
Ethical approval was granted by the North West 1 Research Ethics Committee – 
Cheshire, in 2009 for the study titled ‘Juvenile Myoclonic Epilepsy Cohort’ (Ref: 
09/H1017/55).  Several amendments, including inclusion of seizure diaries, choice of 
length of EEG, and changes to the patient information sheet to the original application 
were made and granted between 2009-2010. With regards to the current study the 
author submitted a substantial amendment that was approved in January 2011. The 
amendment was for the inclusion of the ‘Eysenck Personality Questionnaire-Brief 
Version’ [129], so that the personalities of participants could be assessed. A research 
passport was obtained to gain Research and Development (R&D) approval from 11 
NHS organisations. An honorary contract was granted by R&D at the University 
Hospital of Wales. Indemnity was covered by the University of Liverpool.  
 
 
 
North West n=8 East Midlands n=3 
South East 
n=1 
West Midlands n=1 
Wales n=8 
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6.3 RECRUITMENT 
 
6.3.1 PARTICIPANTS 
In total 78 patients were recruited from five different epilepsy outpatient clinics across 
England and Wales. Four of these patients were excluded from the study as their 
seizures were controlled with AED treatment. One patient was excluded due to their 
inability to complete the assessment due to problems caused by an additional clinical 
illness. Four patients did not attend their pre-arranged neuropsychological assessment, 
and either could not be contacted afterwards or did not wish to arrange a follow up 
appointment. Three patients that were recruited by physicians could not be contacted 
due to insufficient details or change of address. Finally, six patients no longer wished to 
take part in the study once contacted following initial recruitment.   
 
Therefore data from 60 (45 female:15 male) patients with refractory JME were used in 
the analysis. Patients were classified as refractory if they experience ≥1 myoclonic 
and/or absence and/or tonic-clonic seizure per month despite prior or current 
exposure to a dose of at least 1000mg of Sodium Valproate (VPA). The definition of 
drug-refractory epilepsy varies greatly in the literature [130] and has not been defined 
in JME research. The criteria used were based on a combination of the knowledge of 
sodium valproate being effective in 85–90% of the patients with most becoming 
seizure-free [66], the criteria used by others [131, 132] and clinical experience of 
members of the ReJuMEC group. .Exclusion criteria included abnormal MRI brain scan, 
alcoholism, a history of drug abuse, and/or neurological disorder besides epilepsy. In 
addition none of the patients had experienced a GTCS within the 24 hours prior to the 
neuropsychological assessment. For full demographic and clinical characteristics of the 
participants please see Tables 7.1 and 7.2.  
 
Participants were recruited during routine outpatient appointments with epilepsy 
specialists based in major neurological departments in the UK.  Table 6.2 below gives a 
list of sites and number of patients tested at each site. Written informed consent was 
obtained for all participants by either the enrolling neurologist or specialist epilepsy 
nurse, or the author J.W.   
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Table 6.2 Hospitals involved in recruitment and number of patients assessed at each 
site 
Hospital n 
Walton Centre, Liverpool 23 
University Hospital Wales, Cardiff 32 
Kings College London 1 
Royal Hallamshire Hospital, Sheffield 3 
Queen Elizabeth Hospital, Birmingham  1 
Total  number of participants 60 
 
 
6.4 PROCEDURE 
 
The participants were given full instructions of what the study entailed by either the 
recruiting physician or the author J.W. There were four components that participants 
were asked to complete, namely a three month prospective seizure diary, a 48 hour 
ambulatory EEG, a battery of neuropsychological assessments and a blood sample (for 
use in future research). Once recruited participants details were passed on to the study 
co-ordinator who forwarded their details to the relevant parties. Participants were 
then contacted separately to undergo the EEG, neuropsychological assessments and to 
give blood. Participants were not obliged to give blood to take part in the other 
components.   
 
 
6.4.1 PARTICIPANTS RECRUITED AS PART OF THE REJUMEC STUDY 
18 of the participants were recruited and assessed as part of a multicentre study of 
refractory JME, prior to the author’s involvement. These participants were all recruited 
by epilepsy consultants or epilepsy specialist nurses at the Walton Centre, Liverpool 
during outpatient clinics. The study was explained by the recruiting physician and 
informed written consent was obtained. A blood sample was taken (if consent was 
given to do so) by nurses in the outpatient clinic at the time of enrolment into the study. 
An EEG was then arranged by the Clinical Trials Unit in the Walton Centre. The 
neuropsychological assessment was arranged, conducted and scored by a research 
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assistant to Prof G. Baker at the University of Liverpool. The assessments were all 
carried out in the Clinical Trials Unit in the Walton Centre. The same research assistant 
conducted all the assessments.  
 
6.4.2 PARTICIPANTS RECRUITED AS PART OF THE WALES EPILEPSY STUDY 
21 participants were recruited and assessed as part of the Wales Epilepsy Study. 
Participants from this study were given a neuropsychological assessment and asked for 
a blood sample. They were not given seizure diaries or an EEG. Dr R. Thomas recruited, 
gained written consent, took blood or saliva samples, and conducted and scored the 
neuropsychological assessment for all 21 participants.      
 
6.4.3 PARTICIPANTS RECRUITED AND/OR ASSESSED BY THE AUTHOR 
Eight of the participants assessed by J.W were recruited as part of the ReJuMEC study in 
the same way as described above. However, not all participants were recruited and 
assessed at the Walton Centre. Five of these eight participants were recruited by 
consultant neurologists at the Royal Hallamshire Hospital, Sheffield; Kings College 
Hospital, London; and Queen Elizabeth Hospital, Birmingham. The blood samples, 
seizure diaries and EEGs were all organised by the appropriate hospital. The 
neuropsychological assessment however was arranged and conducted by the author at 
the recruiting hospital. Furthermore, these assessments were scored and feedback 
provided by the author.  
 
A further eight participants were recruited by Dr R. Thomas at the University Hospital 
of Wales, Cardiff. Written informed consent and blood samples were obtained by Dr R. 
Thomas. The neuropsychological assessments of these participants were arranged by 
both the author and an administrative member of staff at Swansea University. The 
neuropsychological assessments were conducted at the University Hospital of Wales, 
Cardiff by the author. These assessments were also scored and feedback provided by 
J.W.  
 
Finally the author recruited one participant from an outpatient clinic at the Walton 
Centre, Liverpool. No EEG was conducted, seizure diary given, or blood taken from this 
participant. Informed written consent was obtained by the author prior to conducting 
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the neuropsychological assessment, which was carried out at the participant’s home. 
Lone worker policy was utilised for this assessment to ensure the safety of the author. 
A letter was sent out to patients at the Walton Centre who met the inclusive criteria 
explaining the study and asking for volunteers. Unfortunately no participants were 
gained through this method. 
 
To follow is a brief description of the seizure diary, neurophysiology and genetic 
components of the study. These components were not carried out by the author, 
however some of the data particularly from the seizure dairies was utilised in the 
analysis conducted by the author. A detailed description of the neuropsychological 
assessment will then be given.  
 
6.4.4 SEIZURE DIARY 
In order to gain a detailed account of any ongoing seizure activity participants were 
asked to complete a seizure diary for three months. Participants were supplied with a 
diary whereby they simply had to tick what seizure type (if any) they experienced each 
day.   
 
6.4.5 GENETICS 
Blood samples were collected from 52 participants and saliva from 1. These samples 
were not utilised in the current thesis, but were obtained for future research. 
Participants gave informed consent to take a DNA sample, which was taken by a 
qualified nurse or doctor. Participants were not required to give blood/saliva to take 
part in the current thesis study.  
 
6.4.6 NEUROPSYCHOLOGY 
A standardised battery of neuropsychometric tests was administered to each 
participant. The battery was chosen to enable evaluation of intellectual ability, 
language functioning, verbal and non-verbal memory, frontal lobe mediated executive 
functions, depression, generalised anxiety, patient-perceived cognitive impairment, 
psychosocial impact of JME and personality. Table 6.3 below outlines the assessments 
used and the abilities assessed.  
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Table 6.3 Neuropsychological assessments and questionnaires administered and the 
abilities/difficulties assessed  
Assessment  Reference Description of measures 
Wechsler Adult Scale 
 of Intelligence 3rd 
edition (WAIS-III) 
[133] Measures adult intellectual 
functional: 
 Verbal IQ 
 Performance IQ 
 Full Scale IQ 
 Working Memory 
 Processing Speed 
Wechsler Memory  
Scale 3rd edition 
(WMS-III) 
[134] Measures adult memory ability: 
 General Memory 
 Working Memory 
 Immediate Memory 
  Visual Immediate Memory 
 Auditory Immediate 
Memory 
 Visual Delayed Memory 
 Auditory Delayed Memory 
 Auditory Recognition 
Delayed Memory   
Delis-Kaplan  
executive function 
system (D-KEFS) 
[135] Measures frontal lobe mediated 
executive functions: 
 Verbal Fluency 
 Inhibition  
Boston Naming Test 
(BNT) 
 Measures visual naming ability 
 
Behavioural Assessment 
of the Dysexecutive 
Syndrome (BADS) 
[136] Measures frontal lobe mediated 
executive functions: 
 Planning 
 Inhibition 
 Strategy Formation 
Eysneck Personality 
Questionnaire –  
[129, 137] Measures Personality: 
 Extroversion 
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Brief Version  
(EPQ-BV) 
 Neuroticism  
Hospital Anxiety  
and Depression  
Scale (HADS) 
[138] Measures Mood: 
 Anxiety  
 Depression 
Aldenkamp-Baker 
Neuropsychological 
assessment scale 
(ABNAS) 
 
[139] Measures patient-perceived 
cognitive impairments: 
 Fatigue 
 Slowing 
 Memory 
 Concentration 
 Motor 
 Language 
Impact of Epilepsy [140] Measures psychosocial impact of 
epilepsy 
 
 
 
Wechsler adult scale of intelligence 3rd edition (WAIS-III) [133]  
The WAIS-III is a thoroughly validated assessment in normal populations [141], and 
clinical populations including epilepsy [142]. It is a test that was developed to assess a 
wide range of abilities in an individual, which together provide a detailed insight into 
an individual’s intellectual strengths and weaknesses. Furthermore, it has been used 
repeatedly in JME research [7, 12, 13, 96], thus in the present thesis it was chosen to 
determine the intellectual functioning of refractory JME patients. The accompanying 
manual provides normative data and scoring instructions [133].  
 
Thirteen subtests from the WAIS-III were administered namely, Picture Completion, 
Vocabulary, Digit Symbol, Similarities, Block Design, Arithmetic, Matrix Reasoning, Digit 
Span, Information, Comprehension, Picture Arrangement, Letter-Number Sequence and 
Symbol Search. From these subtests Full Scale IQ (FSIQ), Verbal IQ (VIQ), Performance 
IQ (PIQ), Working Memory (WKM) and Processing Speed index scores were obtained 
for each participant and used in the statistical analyses. Scaled scores were calculated 
using WAIS-WMS writer software for each of the subtests for comparison.  
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Six subtests are combined to calculate the VIQ score, namely Vocabulary, Similarities, 
Arithmetic, Digit Span, Information and Comprehension. These subtests are measures 
of acquired knowledge, verbal reasoning, and attention to verbal material. An 
individual with a deficit in VIQ may be problems with responding to a verbal request, 
this may have implications in the workplace and in social relations. For samples of each 
of these subtests please see Table 6.4 below.  
 
The Vocabulary subtest is designed to measure an individual’s vocabulary level. For the 
Vocabulary subtest participants are asked to define a list of words of increasing 
difficulty. For each item a score of zero, one or two can be given depending on how well 
the participant defines the word.  
 
The Similarities subtest is designed to measure abstract thinking. For this participants 
are verbally presented with two words and asked to explain how they are similar. 
Again a score of zero, one or two can be given depending on how well the participant 
can explain how the two words are similar.  
 
The Arithmetic subtest is designed to measure numerical skills, concentration and 
anxiety. For this subtest participants are verbally presented an arithmetic problem, 
which they must solve mentally. Their answer must be given within a specified time of 
between 15-120 seconds depending on the complexity of the problem. If an answer is 
not given within this time frame a score of zero is given regardless of whether their 
response is correct or not. Each item carries a score of zero or one, with the exception 
of the final two items for which a score of zero, one or two can be given depending on 
the speed of the response.     
 
The Digit Span subtest is designed to measure working memory and anxiety. The 
subtest has two sections (digit forward and digit backward). For the digit forward 
section participants are verbally presented with a series of digits and asked to repeat 
them back in exactly the same order as they were presented. A maximum of eight items 
with a total of 16 unique trials can be presented. The initial item contains two digits, 
and then for each item thereafter a digit is added up to a maximum of nine digits. 
Participants can proceed to the next item if one of the two trials is repeated correctly. 
The section is discontinued if the participant scores a zero on both trials of an item.  A 
score of zero, one or two can be given for each item. For the digit backward section 
participants are given a series of digits in exactly the same way as the digit forward 
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section, but this time participants are asked to repeat the series of digits backwards.  
The digit backward section is slightly shorter with a possible seven items and 14 trials 
available. The maximum amount of digits in a trail is eight. The same discontinue rule 
and scoring applies to the digit backward, as the digit forward.      
   
The information subtest is designed to measures an individual’s range of knowledge. 
For this participants are asked up to 28 general knowledge questions. Each item carries 
a score of zero or one.  
 
The comprehension subtest is designed to measure judgment and social understanding. 
For this subtest participants are verbally presented with questions regarding everyday 
problems and social norms. Responses are scored on how well they describe what they 
would do or why certain things are the way they are in society.  For five of the items 
participants are required to give more than one reason or idea in order to obtain a 
perfect score. Each item carries a score of zero, one or two.  
 
 
Table 6.4 Sample items for the verbal subtests of the WAIS 
Subtest Sample item 
Vocabulary  What does WINTER mean? 
Similarities In what way are PIANO and DRUM alike? 
Arithmetic What is FOUR POUNDS PLUS FIVE POUNDS? 
Digit Span 1. 1       1-7 
2       6-3 
2. 1       5-8-2 
2       6-9-4 
Information What is a THERMOMETER?  
Comprehension  What is the thing to do IF YOU FIND AN ENVELOPE IN THE 
STREET THAT IS SEALED, ADDRESSED AND HAS A NEW 
STAMP ON IT?  
 
 
Five subtests are combined to calculate the PIQ score namely, Picture Completion, Digit 
Symbol-coding, Block Design, Matrix Reasoning and Picture Arrangement. These 
subtest are measures of fluid reasoning, spatial processing, attention to detail and 
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visual-motor functioning [133]. An individual with a deficit in PIQ may struggle with 
convergent thinking; this may cause problems in formal education. For samples of each 
of these subtests please see Table 6.5 below.  
 
The Picture Completion subtest is designed to measure attention to detail. For this 
subtest participants are presented with a series of incomplete pictures (Figure 6.2). For 
each item the participant is asked what important part is missing in the picture. A 
maximum of 25 pictures of increasing difficultly can be presented. Each item carries a 
score of zero or one.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Sample item for the picture completion subtest from the WAIS - a door with 
the handle missing  
 
 
The Digit Symbol-Coding subtest is designed to measure visual-motor functioning and 
processing speed. For this subtest participants are presented with boxes with the 
number 1-9 along the top and symbols in the boxes below. They are then directed half 
way down the page where there are more boxes with the numbers 1-9 in a random 
order, but this time the boxes underneath are empty (Figure 6.3). Thus participants are 
asked to fill in these boxes by drawing a symbol using the code at the top of the page. 
They are asked to work as quickly as they can without skipping any boxes until they are 
asked to stop. Participants are stopped after 120 seconds if they do not fill in all the 
empty boxes. A score of one is given for every correct symbol draw within the time 
frame. 
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Figure 6.3 Sample of Digit Symbol-coding subtest from the WAIS 
 
 
The block design subtest is designed to measure nonverbal reasoning. For this subtest 
participants are presented with nine identical blocks. The blocks are coloured in red 
and white. Some sides are all red, some sides are all white and some sides are half red 
and half white. Participants are asked to copy a printed design with the blocks. For 
items 1-6 a score of zero, one and two can be given. For items 7- 14 a score of zero, four, 
five, six and seven can be given depending on how quickly the participant arranges the 
blocks in the correct design.  
 
 
 
 
 
 
 
 
 
Figure 6.4 Sample item of the block design subtest from the WAIS  
 
 
The Matrix Reasoning subtest is designed to measure an individual’s ability to analyse 
part-whole relationships. For this subtest participants are presented with a series of 
printed patterns that are incomplete, and five options to complete the pattern. They are 
asked to look at each pattern carefully and say which of the five possible options best 
completes the pattern. Each item carries a score of zero or one.  
1 2 3 4 
2 1 3 7 5 
5 6 7 8 9 
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               1                            2                            3                              4                            5     
 
Figure 6.5 Sample item of the Matrix Reasoning subtest from the WAIS 
 
 
The Picture Arrangement subtest is designed to measure planning ability. For this 
subtest participants are given a number of cards with pictures on them, and asked to 
arrange them in an order that makes sense.   
 
Participant’s FSIQ score is calculated from their VIQ and PIQ scores. WKM score is 
calculated from participant’s performance on the digit span and letter-number 
subtests. Finally their processing speed score is calculated from the digit symbol-coding 
and symbol search subtests. 
 
 
Wechsler memory scale 3rd edition (WMS-III) [134] 
The WMS-III is a thoroughly validated in normal populations [134], and clinical 
populations including epilepsy [143, 144]. The WMS has been used repeatedly in JME 
research [13, 14, 72] and was chosen to determine immediate and delayed recall 
ability. Ten subtests were administered namely, Logical memory, Verbal paired 
associates, Faces, Family Picture, Letter number sequencing and Spatial Span. From 
these subtests General Memory, Working Memory, Immediate Memory, Visual 
Immediate and Delayed, Auditory Immediate and Delayed, and Auditory Recognition 
Delayed Memory index scores were obtained for each participant and used in the 
statistical analysis. Scaled scores were calculated using WAIS-WMS writer software for 
each of the subtests for comparison.  
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Auditory memory (immediate and delayed) was calculated from the Logical Memory 
and Verbal Paired Associates scores. These subtests are measures of memory 
functioning when information is presented orally. An individual with a deficit in 
auditory immediate memory may have problems with learning; this may have 
implications in all aspects of life when stimuli are presented in the auditory modality 
[134]. If an individual has a deficit in auditory delay memory they may experience a 
high rate of forgetting. For samples of each of these subtests please see Table 6.5 below.  
 
For the Logical Memory subtest participants are read out two stories and asked to 
immediately recall as much of each of the stories as they can. Story one is read out first 
and recalled, followed by story two. Once the participant has recalled story two the 
story is read out again and the participant is asked to recall it once more. Participants 
are then asked to recall both stories following a 30 minute delay.  
 
For the Verbal Paired Associates subtests participant are read out a list of eight word 
pairs. The first word of each pair is then repeated and the participant is asked to say 
which word goes with BANK for example. The list of pairs is read out four times and 
recalled four times (once every time the list is read out). Participants are then asked to 
recall the pairs once more after a 30 minute delay.  
 
 
Table 6.5 Sample items for the Verbal memory subtests of the WMS 
Subtest Sample item  
Logical Memory Anna Thompson of South London who 
was employed as a cook in a school 
canteen...... 
Verbal Paired Associates Truck-Arrow 
Insect-Acorn 
Reptile-Clown 
 
 
Visual memory (immediate and delayed) was calculated from the Faces and Family 
Pictures scores. These subtests are measures of memory functioning when information 
is presented visually. Similar problems in learning and forgetting that were described 
above in relation to auditory memory apply to visual memory. In addition to this the 
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delayed visual subtests comprise of one recall paradigm (family pictures) and one 
recognition paradigm (faces). Thus a difference in performance on the two subtests 
may suggest meaningful differences in memory functioning. For example, a low score 
on the Family Pictures subtest, and high score on the Faces subtest may indicate a 
retrieval problem [134].  
 
For the Faces subtest participants are presented with 24 faces for two seconds one at a 
time, which they are asked to remember. They are then presented with a group of 48 
faces, and asked to say yes if a face is one from the group I asked them to remember or 
no if it is a new face. A score of zero or one can be given, depending on if the participant 
correctly identifies each face.  Following a 30 minute delay participants are asked to 
correctly pick out the faces they were asked to remember from a new group of 48 faces. 
The scoring is the same as the immediate recall task.  
 
For the Family pictures subtest participants were first presented with a picture of a 
family of five family members (Grandfather, Grandmother, Father, Mother, Son and 
Daughter) and a dog. They are then presented with four scenes with these family 
members and the dog in them for 10 seconds each. They are then asked to recall who 
was in the scene, where they were and what they were doing for each scene. Following 
a 30 minute delay participants are then asked to recall the four scenes again. For each 
correctly recalled character a score of one is given. For each correctly recalled location 
of a character a further score of one is given. Finally for each activity recalled a score of 
zero, one or two is given, depending on how accurately the participant describes what 
each character was doing. The scoring is the same for the immediate and delayed recall.  
 
Auditory Recognition Delayed Memory was calculated from the Logical Memory 
recognition score and the Verbal Paired Associates recognition score. For the Logical 
Memory recognition participants were asked 15 question on story one and 15 question 
on story two. They were asked to simply say whether the statement is true or not. For 
the Verbal Paired Associates recognition participants were read out a list of 24 word 
pairs, which contained both the pairs they had learnt and new pairs. Participants were 
asked to say ‘yes’ if the pair was one they had learnt or ‘no’ if it was a new word pair. 
Please see Table 6.6 below for samples of the recognition subtests. 
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Table 6.6 Samples of the recognition subtests from the WMS 
Subtest  Sample item 
Logical Memory Recognition 
 
Verbal Paired Associates Recognition 
Was the women’s name Anna Thompson? 
Rose-Bag 
Queen-Thumb 
Elephant-Glass 
 
 
Immediate memory was calculated from the immediate recall scores from the Logical 
Memory, Verbal Paired Associates, Faces and Family Pictures subtests. General memory 
was calculated from the delayed recall scores from the Logical Memory, Verbal Paired 
Associates and Family Pictures subtests.  
  
Delis-Kaplan executive function system (D-KEFS)[135] 
The D-KEFS was chosen to assess language, fluency, attention and executive functions. 
It is also a thoroughly validated test [145], and comes with normative data and a 
scoring manual [135]. The subtests administered were Verbal Fluency, which included 
Letter, Category and Category Switching; and Colour-Word Interference, which 
included an adaptation of the Stroop Test [146].  
 
The Verbal Fluency subtest was used to examine the patient’s ability to generate words 
fluently. The letter task included naming as many words as possible in 60 seconds 
beginning with a particular letter. This was repeated for the letters F, A and S. For the 
category task participants were asked to name as many animals as they could, followed 
by as many boys’ names as they could, both in 60 seconds. Lastly, for the category 
switching task participants were asked to switch between saying as many fruits, and as 
many pieces of furniture as they could in 60 seconds. The number of words generated 
and rule breaks were calculated and used in the analyses. 
 
The Colour-Word Interference task was used to examine patient’s ability to inhibit an 
over learned verbal response in order to generate a conflicting response of naming the 
dissonant ink colours in which the words are printed. The task includes 4 trials. For 
trial one the examinee is to simply say the colour of the ink squares are printed in. For 
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trial two they are asked to read a sequence of colour words printed in black ink. For 
trial three participants must name the colour of the ink of non matching colour words. 
Finally, for trial four participants were asked to do the same as the previous trial with 
the additional task of reading the written word not the ink colour if the word was in a 
box. The time it took participants to complete each trial and the number of mistakes 
and corrections were used in the analyses. See Figure 5.6 below for illustrations of each 
of the trials.   
 
 
Trial one: 
 
                  
 
 
Trial two: 
           green     red     blue     green     blue       
 
Trial three:   
                   blue     green     blue     red     blue  
 
Trial four:  
                 green     blue     green     blue      red   
 
 
Figure 6.6 Sample of each of the four trials in the Colour-Word Interference task from 
the D-KEFS  
 
 
Boston naming test (BNT) 
The BNT was chosen to assess visual naming ability. The standard form was used in the 
present study. Participants were presented with pictures and asked to name the object 
depicted. All participants in the current study were administered items 30-60. If a 
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participant was incorrect on any of the items 30-38 they were administered items in 
reverse order from 29 until 8 consecutive correct responses. The number of correct 
responses was used in the analyses.  
 
 
                                                                                                       
 
 
 
 
 
 
Figure 6.7 Sample item from the Boston Naming Test 
 
Behavioural Assessment of the Dysexcutive Syndrome (BADS) [136] 
The BADS was included as an additional test of executive functions that has good 
ecological validity [147].  The BADS comes with normative data and a scoring manual 
[136]. The subtests administered were the Rule Shift, Key Search and Zoo Map. For 
each test a profile score was calculated and used in the analyses. For classification of 
profile scores see Table 6.7 below. 
 
Table 6.7 Classification of profile scores 
Profile score Classification 
4 Above average 
3 Average 
2 Below average 
1 Borderline 
0 Impaired 
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The Rule Shift was chosen to assess the participant’s ability to follow and shift between 
rules. The test comprises of two trials. In the first trial participants were presented 
with 21 spiral bound non-picture playing cards and the rule ‘Say yes to red cards and 
no to black cards’, which was both read out to them and placed in front of them for the 
duration of the trial. The examiner turned over the playing cards one at a time, waiting 
for the participant’s response before turning over the next card. In the second trial 
participants were presented with the same playing cards, but a different rule ‘Say Yes if 
the card that has just been turned over is the same colour as the previously turned card 
and no if it is a different colour’, which was read out and placed in front of them. The 
examiner turned over the playing cards one at a time, waiting for the participant’s 
response before turning over the next card. In both trials the number of errors and time 
taken was recorded A profile score was calculated based on the performance on the 
second trial. 
 
The key Search was chosen to assess strategy formation and participant’s ability to self-
monitor. Participants were presented with an A4 piece of paper with a 10cm square in 
the middle and a small black dot 5cm below it. The participants were told to ‘imagine 
the square is a large field, which you have lost your keys in. Draw a line starting from 
the black dot to show where you would walk to search the field to make absolutely 
certain that you would find your keys. Tell me when you are finished.’ The time taken 
was recorded, and this and the strategy used was used to calculate a profile score. 
 
The Zoo Map was included to assess planning ability. This task consisted of two trials. 
In both trials participants were presented with an A4 piece of paper, which had a map 
of a zoo on it. Above the map were instructions of six locations (out of 12) on the map 
they were required to visit. They were also given a set of rules they must obey when 
planning their route around the zoo. They rules included; starting at the entrance, 
finishing at the picnic area, only using paths once unless the path has a dotted pattern 
in which case the path can be used twice, and only using the monorail once. In the first 
trial participants are not given any instructions other than the rules and a list of six 
locations they must visit in an order they choose. In the second trial as well as the rules 
they are given the order in which they must visit the six locations. The time taken and 
number of rules broken was recorded and used to calculate a profile score.     
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Eysenck Personality Questionnaire – Breif Version (EPQ-BV) [129, 137] 
The EPQ-BV was included to examine the presence of personality disorders (PDs) in 
JME, and whether PDs are related to severity of seizures, cognitive impairments and 
executive dysfunction. The EPQ-BV [129] is a 24-item short version of the EPQ-R, which 
was developed from the original Eysneck and Eysneck EPQ [148]. It is a self-report 
questionnaire that measures two personality dimensions, namely extroversion (E) and 
neuroticism (N).  
 
The EPQ-BV was chosen over previous versions of the EPQ [148] due to the brevity and 
likert scale format. Alternative personality tool have been employed in the few 
previous studies that have investigated personality in JME i.e. the Minnesota 
Multiphasic Personality Inventory (MMPI) [149],  the Structured Clinical Interview for 
the DSM-IV (SCID) [26, 27] and the Youth Self-report (YSR) and Weinberger 
Adjustment Inventory (WAI) [98]. The above personality assessments were not used 
for the following reasons: the YSR and WAI were designed for participants aged 
between 10-17 years, thus both were not appropriate for the current sample. The 
MMPI was eliminated as it contains 567 questions with the facility to answer only 
“true” or “false”. Finally the SCID could not be used as a Psychiatrist is required to 
administer it, and thus was too costly in time and money for the current investigation.  
 
The EPQ-BV is quick and easy to administer and complete, and appropriate for the age 
range of the current sample. Moreover, it has good re-test reliability and validity [129]. 
The coefficient alpha scores for the EPQ-BV have been reported to be .92 and .90 for E 
and N, respectively [129, 137]. The EPQ-BV is scored on a likert scale from A (not at all) 
to E (extremely), where A=1, B=2, C=3, D=4 and E=5. Items 13 and 19 are reverse 
scored. Table 5.8 below gives a sample of the EPQ-BV. 
Table 6.8 Sample of EPQ-BV 
Sub-scale Sample Question Response Score 
Extroversion 
 
Are you a talkative person?  Not at all 
 Slightly 
 Moderately  
 Very much 
 Extremely  
1 
2 
3 
4 
5 
Neuroticism Does your mood often go 
up and down? 
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Hospital anxiety and depression scale (HADS) [138] 
The HADS was chosen to assess the participant’s level of anxiety and depression. Mood 
has long been found to be a factor in cognitive performance, thus the HADS was used to 
examine the impact mood has on the cognitive performance in the current sample. The 
HADS is well established as a reliable tool for measuring anxiety and depression in 
patient groups [150]. Acceptable internal consistencies and high re-test reliability 
correlations have been reported internationally [151, 152]. Another advantage is its’ 
brevity, especially when participants are already faced with a lengthy and tiring 
assessment.  
 
The HADS is a self-report questionnaire that consists of seven questions for the 
depression subscale, and seven questions for the anxiety subscale. Participants are 
asked to rate each item based on how they have been feeling in the previous week on a 
4-point likert scale. Anxiety and depression items are scored separately with each item 
carrying a score of 0-3. An overall score for either subscale of 0-7 equates to normal 
levels, 8-10 to mild levels, 11-14 to moderate levels, and 15-21 to severe levels of 
anxiety or depression (Table 6.9 presents a sample of both subscales). The scores for 
both subscales were used in the analyses.   
 
Table 6.9 Sample of HADS 
Sub-scale Sample Question Response Score 
Anxiety  I feel tense or 
‘wound up’ 
 Most of the time 
 A lot of the time 
 Time to time 
 None of the time 
3 
2 
1 
0 
Depression  I still enjoy the 
things I use to enjoy 
 Definitely as much 
 Not quite as much 
 Only a little 
 Hardly at all 
0 
1 
2 
3 
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Aldenkamp-Baker Neuropsychological assessment scale (ABNAS) [139] 
The ABNAS was included to assess the relationship between patients perceived level of 
cognitive effects of their AEDs, and their actual level of cognition based on an objective 
neuropsychological assessment. The ABNAS is a self-report questionnaire that has been 
found to be a valid instrument for identifying drug induced cognitive impairments in 
patients with epilepsy [139].  
The ABNAS assesses six aspects of cognition that are sensitive to neurotoxicity of AEDs, 
namely Fatigue, Slowing, Memory, Concentration, Motor and Language. The Scale 
consists of five items for both the fatigue and slowing subscales, four items for the 
memory and concentration subscales, and three items for the motor and language 
subscales. Participants were asked to rate to what extent 24 statement are true to them 
on a 4-point likert scale (0=no problem to 3=a serious problem). A score for each of the 
subscales was totalled. Each subscale score was then added together to produce an 
overall total score, which ranged from 0-72. The total score was used in the analysis. 
For a sample of the ABNAS please see Table 6.10 below. 
 
Table 6.10 Sample questions for each of the subscales from the ABNAS         
Sub-scale Sample Question Response and score 
Fatigue I am less enthusiastic 
about day to day activities 
 
 
 No problem  = 0 
 
 Mild problem = 1 
 
 Moderate problem = 2 
 
 Serious problem = 3 
Slowing My mind does not work as 
fast as it should 
Memory 
 
 
Concentration 
 
I have difficulties 
remembering people’s 
names 
I have difficulties in 
following books or films 
Motor I feel clumsy 
Language I have problems finding 
the correct words 
Total score  0-72 
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Impact of Epilepsy Scale (IES) [140] 
The impact of epilepsy scale was utilised to assess the impact of epilepsy and AED 
treatment on various aspects of participant’s daily lives, including their relationships 
with friends and family, social life, employment, health, self-esteem, plans for the future 
and standard of living. Acceptable alpha coefficients have been reported for the scale 
[140]. In addition high correlations between psychological wellbeing and perceived 
impact of epilepsy, indicate good construct validity [140]. 
 
It is comprised of 10 items rated on a 4-point likert scale from ‘a lot’ to ‘not at all’. With 
the exception of items one and five, which have an additional option of ‘not applicable’. 
A score of 8-20 represents mild impact, 21-30 represents moderate impact, and a score 
of 31-40 represented severe impact. For a sample of the IES please see Table 6.11 
below. The total score was used in the analyses.     
 
Table 6.11 Sample questions from the Impact of Epilepsy Scale         
 Sample Question Response Score 
Impact of 
epilepsy scale 
To what extent have 
your personal 
relationships been 
affected? 
 A lot 
 A moderate amount 
 A small amount 
 Not at all 
4 
3 
2 
1 
 
 
6.5 STATISTICAL ANALYSIS  
 
6.5.1 POWER CALCULATION 
A power calculation was conducted by the author J.W using Minitab 16 statistical 
package. The primary outcome measure was verbal inhibition from the D-KEFS. This 
outcome measure was chosen as it is the most consistent executive function 
impairment reported in JME [16]. The power calculation revealed that 32 participants 
were needed to detect a significance difference of 2.22 between the refractory JME 
group and manual means, setting the probability of making a type 1 error at 0.05. 
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6.5.2 DATA ENTRY 
The data collected from the 60 participant’s was inputted into a database designed and 
maintained by the author. All the assessments were scored according to the manuals 
provided with each of the tests, and checked before being entered into a database using 
the Statistical Package for Social Sciences (SPSS) version 19.0.  
 
6.5.3 STATISTICAL PROCEDURE USED 
Due to the number of multiple comparisons being made, and to reduce the likelihood of 
making Type I error the significance level was set at p< .01 for all independent sample 
t-tests. Bonferroni correction was not applied as this would have given too 
conservative a value (0.05/41= p<.001) due to the number of inferential statistics 
conducted, and therefore would have increased the likelihood of making a Type II 
error. The use of a significance level of p<.01 has been used by others [114, 153] 
 
6.5.3.1 Demographic and clinical characteristics 
Demographic characteristics that were recorded and used in the analyses were gender, 
age, years of education, level of education (school, college or university), WAIS full IQ 
index score, and employment status. For the continuous variables histograms were 
produced and skew and standard error statistics. Means and standard deviations were 
reported for data that met the normal distribution. If data were considered skewed 
from the normal distribution the median and inter-quartile ranges were reported. The 
latter applied to the variables age and years of education. The mean and standard 
deviation were reported for the WAIS IQ index score.   
 
Clinical characteristics that were recorded and used in the analyses were age of onset, 
duration of epilepsy, family history, history of febrile seizure, photosensitivity, seizure 
type, seizure frequency, number of AEDs, and AED type. For the continuous variables 
histograms were produced and skew and standard error statistics. Means and standard 
deviations were reported for data that met the normal distribution. If data was 
considered skewed from the normal distribution the median and inter-quartile ranges 
were reported. The latter applied to the variables age of onset and duration of epilepsy.   
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6.5.3.2 Neuropsychological profile  
The neuropsychological assessment administered to all the participants produced an 
age adjusted score for each cognitive domain assessed. The spread of these scores was 
determined by visual analysis of histograms, and consideration of the skew and 
standard error statistics. Each of the index score from the WAIS and WMS were 
normally disturbed apart from processing speed. Therefore the means and standard 
deviations were used to describe central tendency for all but processing speed, for 
which the median and inter-quartile range was reported.  
 
For the subtests of the WAIS and WMS the same procedure was carried out. For the 
variables digit-symbol coding, faces (immediate and delayed recognition), family 
pictures (delayed recall) and spatial span the median and inter-quartile ranges were 
reported. The remaining subtests were normally distributed, and thus their means and 
standard deviations were reported.  
 
In order to compare the participant’s scores to a healthy population, z-scores were 
calculated based on the means and standard deviations given by the assessment 
manuals.   
 
To control for and assess the impact of education, intellectual functioning scores were 
correlated with years in education using Pearson’s R correlation coefficients. Pearson’s 
was chosen as the scores fitted assumptions of normality.  Post hoc t-tests were run for 
any variables that were highly correlated.  
 
6.5.3.3 Impact of contributory factors on neuropsychological profile 
In order to determine the impact of the contributory factors outlined in Table 4.2 (and 
described in detail in Chapter four) on the neuropsychological profile of the sample, 
bivariate correlation and regression analyses were conducted. Standard linear 
regression was chosen to assess the predictive power of the variables and to identify 
which factors significantly contributed to the explanation of variance in cognition. This 
analysis has been utilised in previous reports investigating the neuropsychological 
profile of JME patients.  
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For each cognitive test with a z-score >1.00 SD below published norms a univariant 
regression was run for each clinical and mood variable (age of onset, duration of 
epilepsy, types of seizures, frequency of seizure types, number of AEDs, HADS 
depression score and HADS anxiety score). Multivariable regression with forward 
variable selection was then run for further investigation of any cognitive test with more 
than one significant predictor.  
 
Post-hoc analyses of significant findings were assessed using independent sample t-
tests.  
  
6.5.3.4 Personality and neuropsychological functioning 
To assess whether an abnormal personality is related to neuropsychological 
functioning, the data from the EPQ-BV was dichotomised into ‘high’ and ‘normal’ 
neuroticism, and ‘low’ and ‘normal’ extroversion. The neuroticism scores were split 
into ≥40 for females, and ≥37 males. A score of 40 or above for females and 37 or above 
for males is one standard deviation above the means given by Sato [137]. The 
extroversion score was split into ≤33 for both males and females.  A score of 33 or less 
is one standard deviation below the means given by Sato [137].  
  
The performance across the battery of the participants in each personality group was 
compared to published norms using z-scores. Their performance was then compared 
across groups with independent sample t-tests.  
 
Patients were then grouped into those with high neuroticism and/or low extroversion, 
and those with normal levels of neuroticism and extroversion. These two groups were 
coded as abnormal personality and normal personality, respectively. To assess the 
effect of abnormal personality traits overall on neuropsychological functioning, one 
sample t tests were conducted between published norms and abnormal personality 
group, and normal personality group.  
 
Three additional executive function tests were administered to half of the sample, 
namely the rule shift, key search and zoo map from the BADS. The samples mean scores 
were compared to manual means by one sample t-tests. A significant difference was 
found for the zoo map. Pearson’s correlation was conducted between zoo map score 
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and personality, psychiatric characteristics, clinical characteristics and years of 
education. A significant correlation between neuroticism and zoo map score. Post-hoc 
independent t-tests were conducted to investigate the effect of neuroticism on zoo map 
performance.  
 
6.5.3.5 Severity of executive dysfunction 
Executive function tests were divided into six executive functions, and the z-scores of 
each of the tests were calculated. In concordance with previous research [154, 155] a z-
score of ≤-1 (one or more standard deviations below the manual means) on at one of 
the tests within each of the six domains was categorised as having executive 
dysfunction in relation to that domain. As naming ability was measured by only one test 
a z-score of ≤-1 on the Boston naming test was categorised as executive dysfunction in 
relation to naming ability. If two domains were found to meet these criteria the patient 
was said to have mild executive dysfunction. If three or four domains met the criteria 
the patient was said to have moderate executive dysfunction. If five or more domains 
met the criteria the patient was said to have severe executive dysfunction. 
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CHAPTER SEVEN – RESULTS: DEMOGRAPHIC 
AND CLINICAL CHARACTERISTICS 
 
 
7.1 DEMOGRAPHIC CHARACTERISTICS (TABLE 7.1) 
 
In total 60 patients diagnosed with refractory JME were assessed on their intellectual 
functioning, memory, and executive functions. In addition patient’s psychological 
wellbeing and personality were also examined. Prior to assessment demographic and 
clinical history was recorded. The demographic and clinical characteristics of the 
current sample are displayed in Tables 7.1 and 7.2, respectively. 
 
The majority of the sample were female (75%) and had a median age of 31 years (range 
19 – 67 years). All patients had achieved at least a secondary school education with the 
median number of years of formal education being 13.0 years; 38% had a college 
educational and 13% graduated from University. Sixty-seven percent were currently in 
employment, 5% in education and the remainder were unemployed.  
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Table 7.1 Participants’ demographic characteristics 
  n = 60 
Gender  Female 45 (75.0%) 
Male 15 (25.0%) 
Age  
 
Median 31.00 
IQR 24.00, 38.75 
Number of years in formal 
education 
Median 13.00 
IQR 11.00, 13.00 
Level of education (n=40) School 20 (50.0%) 
College 15 (37.5%) 
University 5 (12.5%) 
WAIS full scale IQ Mean  89.25 
SD 15.24 
Employment status (n=39) Employed 26 (66.7%) 
Unemployed  11 (28.2%) 
Full time 
education 
2   (5.13%) 
SD, standard deviation; IQR, Inter-quartile range; WAIS, Wechsler Adult Intelligent Scale 
 
7.2 CLINICAL CHARACTERISTICS (TABLE 7.2) 
 
The clinical characteristics of the current sample of JME are in concordance with JME 
profiles reported previously [13, 14, 16]. The median age of onset was 12.00 years, with 
the median duration of epilepsy being 21.00 years. All of the patients (100%) had or 
continue to experience myoclonic seizure. The majority of patients also had 
experienced GTCS (96%), and almost two thirds had experienced absences (70%). In 
addition two patients had experienced atonic/astatic seizures, while another single 
patient had experienced drop attacks. Photosensitivity was reported by nine of the 
patients.  
 
Two-thirds returned seizure diaries; 50% continued to experience at least one 
myoclonic seizure per day (only 7.5% reported abatement of these seizures) (Fig 7.1). 
In contrast, 37.5% of the patients had controlled GTCS, and 5% had never had a GTCS. 
The frequency of GTCS for the remaining 57.5% ranged between one per week to one 
per year (Fig 7.2). Forty percent of the patients had never experienced an absence 
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seizure. However, for those who did, they were found to be very frequent. 25% 
experienced one or more per day and all together 50% experienced one or more per 
month, while only 5% were controlled (Fig 7.3). 
 
A small minority of the sample had a history of febrile seizures (n=6, 11.1%). A family 
history of epilepsy was more prevalent with 25 patients (43.9%) reporting at least one 
member of their family had or has epilepsy. Of these 25 patients about two thirds of 
them reported one family member related by at least the 3rd degree having also been 
diagnosed with epilepsy, while nearly a quarter of these patients reported two or more 
cases of epilepsy in their families.  
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Table 7.2 Participant’s clinical characteristics 
   
Duration of epilepsy (years)  
(n = 57) 
Median 20.00 
 IQR 9.50, 30.00 
Onset of epilepsy (years) (n= 57) Median  13.00 
 IQR 9.00, 15.00 
Types of seizure  Myoclonic  60 (100%) 
 GTCS (n=54) 52 (96.3%) 
 Absences (n-54) 38 (70.4%) 
 Other 2 (3.4%) 
Family history (n=57)  25 (43.9%) 
History of febrile seizures (n=54)  6 (11.1%) 
Photosensitive (n=33)  9 (27.3%) 
Number of AEDs  1 28 (46.7%) 
 2 20 (33.3%) 
 3 or more 12 (20.0%) 
AED type  VPA 35 
 LEV 25 
 LTG 18 
 TPM 10 
 ZNS 4 
 CLB 10 
 CBZ 2 
IQR, Inter-quartile range; Myo, myoclonic seizures; Ab, absence seizures; TC, tonic clonic 
seizures; VPA, Sodium Valproate; LEV, Levetiracetam; LTG, Lamotrigine; TPM, Topiramate; ZNS, 
Zonisamide; CLB, Clobazam ; CBZ, Carbamezepine.  
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 Figure 7.1 Frequency of myoclonic seizures (n=40) 
 
 
 
 
 
Figure 7.2 Frequency of GTCS (n=40) 
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Figure 7.3 Frequency of absence seizures (n=40) 
 
 
7.2.1 Anti-epileptic medication at testing 
In the current sample seven different AED’s were prescribed, with VPA being the most 
common.  As would be expected in a refractory sample, over half of the patients were 
on polytherapy (n=32), while 28 patients (47%) were on monotherapy; 20 (33%) were 
taking two; 11 (18%) were taking three; and one individual was taking four. The 
monotherapy AEDs were valproate (n=17, mean daily dose 1464mg); lamotrigine (n=5, 
mean daily dose 300mg); levetiracetam (n=4, mean daily dose 2500mg); and 
zonisamide and topiramate were both taken by single individuals. Of the people taking 
two AEDs there were 12 different combinations, the most common of which was 
valproate and levetiracetam (n=5) followed by valproate and lamotrigine (n=3). There 
were six different combinations of three AEDs taken concurrently, four of these 
included clobazam as an adjunct. 
 
7.3 PERCEIVED EFFECTS OF AEDS ON COGNITIVE FUNCTIONING  
 
Perceived cognitive functioning assessed with the ABNAS (see method chapter for 
description). Means reported by Aldenkamp et al [156] were used for comparison with 
the current sample. They reported a mean of 19.46 and standard deviation of 15.8 from 
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a sample of 96 people with epilepsy (consisting of 55 well controlled patients on 
monotherapy and 41 refractory patients on polytherapy) [156]. One sample t-tests 
were conducted with a test value of 19.46 to compare the current samples ABNAS 
scores to the means reported by Aldenkamp et al. The findings from these tests are 
displayed in Table 7.3 below  
 
 
Table 7.3 Current samples ABNAS score compared to healthy means  
 N Mean (SD) Sig.  
Total ABNAS score 35 36.9 (16.0) < .001 *** 
                                                ***P ≤.001 
 
 
 
 
 
Figure 7.4 Current samples scores across the six sub-scales of the ABNAS 
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Figure 7.4 illustrates the current samples scores across the six sub-scales of the ABNAS. 
The box plots indicates that the least subjective complaint reported on average was 
motor abilities. The most subjective complaint reported on average was mental 
slowing. However, both motor and mental slowing produced the largest range of 
scores.  
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CHAPTER EIGHT – RESULTS:  
NEUROPSYCHOLOGICAL PROFILE  
 
 
Hypothesis one: SIGNIFICANT IMPAIRMENTS IN 1) INHIBITION 2) VERBAL FLUENCY. 
AS THE PATIENT GROUP INVESTIGATED IN THE CURRENT THESIS CONSISTS OF ONLY 
REFRACTORY PATIENTS IT IS HYPOTHESISED THAT OTHER COGNITIVE IMPAIRMENTS MAY BE 
REVEALED. 
 
Previous investigations have consistently reported impairments in neuropsychological 
functions in patients diagnosed with JME [7, 11-14, 16, 22, 72, 106, 154, 157]. 
Therefore the current study hypothesised that significant impairments would be found 
for inhibition and verbal fluency. To investigate this hypothesis participants were 
administered a series of neuropsychological assessments. The means and standard 
deviations of these assessments are displayed in Table 8.1 below. 
 
No control group was recruited in the current study. Therefore, in order to compare the 
participant’s scores to the mean scores of a healthy population, z scores were 
calculated based on the means and standard deviations given by the assessment 
manuals. Each of the assessments provides standardised scores for the ages 16-89. The 
z scores were calculated using the following equation: 
                                     Z = 
    
 
  
The z scores for the WAIS, WMS and D-KEFS are given in table 8.1. Box plots of these 
scores are also presented (figures 8.1-8.3) to better illustrate the current samples 
scores, compared the standardised means. 
 
8.1 Intellectual function 
The mean FSIQ was 89 for the cohort (range 55 - 117). VIQ, PIQ, PS, WM and the FSIQ 
(Table 8.1) were all lower in people with drug-refractory epilepsy than standardised 
means; PS was lowest.  Eight participants (13%) returned FSIQs two SDs below the 
mean (i.e. an IQ of 70 or below).   
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Table 8.1: Intellectual functioning as measured by the WAIS of patients with drug-
refractory JME compared to healthy standardized controls.    
 
Neuropsychological test  
Mean (SD)  
scaled score  
Standardised 
norms (SD) 
Mean adjusted 
z score 
Full Scale IQ 89.2 (15.37) 100 (15) -.718 
Verbal IQ  88.8 (15.30) 100 (15) -.689 
Performance IQ 91.4 (15.25) 100 (15) -.570 
Processing Speed  86.0 (79.5, 99.0) ᵅ 100 (15) -.930 
WAIS Working Memory 88.8 (18.41) 100 (15) -.644 
Vocabulary 8.4 (3.23) 10 (3) -.532 
Similarities 8.0 (3.13) 10 (3) -.673 
Arithmetic  7.9 (3.63) 10 (3) -.842 
Digit Span 8.5 (2.85) 10 (3) -.485 
Information 8.3 (2.89) 10 (3) -.577 
Comprehension  8.0 (3.65) 10 (3) -.661 
Picture Completion  9.1 (3.37) 10 (3) -.300 
Digit Symbol-coding  7.0 (5.0, 7.0) ᵅ 10 (3) -1.00 
Block Design 8.6 (2.51) 10 (3) -.468 
Matrix Reasoning 9.6 (3.19) 10 (3) -.135 
Picture Arrangement 8.3 (2.88) 10 (3) -.574 
Letter-Number 
Sequencing 
8.7 (3.59) 10 (3) -.425 
Symbol Search 8.3 (3.32) 10 (3) -.553 
 
ᵅ Median and inter-quartile range 
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8.2 Memory performance 
Immediate memory (particularly immediate visual memory), delayed visual memory, 
general memory and WM were all lower in participants than published norms (Table 
8.2). The lowest scores were seen in immediate visual memory (mean= 88). Of the 
subtests that compose these measures patients scored worse on verbal paired 
associates, faces, family pictures (immediate and delayed) and spatial span.  
 
 
Table 8.2: Memory function as measured by the WMS of patients with drug-refractory 
JME compared to healthy standardized controls.    
 
Cognitive Test 
JME means 
(SD) 
Standardised 
norms (SD) 
Mean 
adjusted z-
score 
Immediate Memory 90.5 (13.07) 100 (15) -.635 
Immediate Visual 
Memory 
87.6 (14.11) 100 (15) -.827 
Delayed Visual 
Memory 
88.2 (19.44) 100 (15) -.679 
Immediate Auditory 
Memory 
95.8 (12.50) 100 (15) -.277 
Auditory Recognition 
Memory 
100.4 (14.72) 100 (15) .039 
General Memory 95.2 (13.43) 100 (15) -.321 
WMS Working 
Memory 
90.4 (15.45) 100 (15) -.644 
Logical Memory: 
immediate recall 
9.8 (2.94) 10 (3) -.056 
Logical Memory: 
delayed recall 
10.5 (2.58) 10 (3) .230 
Verbal Paired 
Associates: 
immediate recall 
8.6 (2.54) 10 (3) -.459 
Verbal Paired 
Associates: Delayed 
9.6 (2.60) 10 (3) -.132 
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recall 
Faces: immediate 
recognition 
8.0 (7.0, 9.0) ᵅ 10 (3) -.670  
Faces: delayed 
recognition  
9.0 (7.0, 11.0) ᵅ 10 (3) -.310 
Family Pictures: 
immediate recall 
7.6 (2.83) 10 (3) -.793 
Family Pictures: 
delayed recall  
8.0 (5.0, 10.0) ᵅ 10 (3) -.780 
Spatial Span 8.0 (6.0, 10.0) ᵅ 10 (3) -.707 
ᵅ Media and inter-quartile range 
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8.3 Executive function 
Participants scored worse on all tests of verbal fluency and executive function (Table 
8.3). The two most poorly performed tests were inhibition switching and the BNT.  
 
Table 8.3: Executive functioning of patients with drug-refractory JME compared to 
healthy standardized controls. 
Cognitive test 
JME mean 
(SD) 
Published 
norms (SD) 
 
Mean 
adjusted z-
scores 
Letter Fluency 7.4 (3.30) 10 (3) -.867 
Category Fluency 7.9 (4.24) 10 (3) -.707 
Category Switch  8.6 (3.88) 10 (3) -.477 
Category Accuracy  9.2 (3.69) 10 (3) -.259 
Inhibition 7.8 (4.33) 10 (3) -.740 
Inhibition switch 6.0 (4.48) 10 (3) -1.34 
BNT 49.1 (9.0) 55.5 (3.9) -1.64 
 
 
The performance of the current sample compared to standardised norms illustrated in 
Figures 8.1-8.3 below. The index scores for the WAIS and WMS, and scores from the D-
KEFS are displayed alongside the standardised norms.  
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Figure 8.1 Mean WAIS index scores and standardised norms 
 
 
Figure 8.2 Mean WMS index scores and standardised norms 
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Figure 8.3 Mean D-KEFS scores and standardised norms 
 
 
8.4 Education 
To control for and assess the impact of education intellectual functioning, memory and 
executive function scores were correlated with years in education using Pearson’s R 
correlation coefficients. This revealed significant relationships between years of 
education and verbal IQ [r= .497, df= 40, p< .001], full scale IQ [r= .422 df= 39, p<.05], 
auditory immediate memory [r= .340, df= 39, p<.05], auditory delayed memory [r= 
.373, df= 39, p< .05], and verbal inhibition [r= .375, df= 37, p< .05].  
 
Post hoc t-tests were run to investigate these relationships. The sample was split into 
those who had received ≥11 years of education, and those who had received <11 years 
of education. The means and SDs of the two groups for the five correlated variables (full 
scale IQ, verbal IQ, auditory immediate and delayed memory, verbal inhibition) were 
compared. The t-tests with alpha level set at p< .01 revealed significant differences in 
verbal IQ, auditory immediate memory and auditory delayed memory. The difference in 
full scale IQ scores and verbal inhibition scores failed to reach significance. Those with 
≥11 years of education had significantly higher verbal IQ scores [t(39)= 2.018, p< .05], 
auditory immediate memory [t(38)= 2.261, p< .05] and auditory delayed memory 
[t(38)= 2.504, p< .05] than those with <11 years of education.  
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When the scores of the two groups were compared to manual means the performance 
of patients with ≥11 years of education did not significantly differ for auditory 
immediate (p= .612) or delayed (p= .159) memory. However, their performance was 
significantly poorer for verbal IQ (p= .019). The patients with <11 years of education 
performed significantly worse than manual means on all three cognitive domains; 
verbal IQ (p< .001), auditory immediate (p= .007) and delayed (p= .044) memory. Thus, 
receiving formal education for ≥11 years protects against impairments in auditory 
immediate and delayed memory, but it does not protect against significantly worse 
performance on verbal IQ. However, although patients with ≥11 years of education 
performed worse they still scored within the normal range for verbal IQ (mean = 
91.22), while those with <11 years of education scored at the lower end of the below 
average range (mean = 81.72).     
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CHAPTER NINE – CONTRIBUTORY FACTORS 
 
 
HYPOTHESIS TWO: CLINICAL CHARACTERISTICS AND MOOD WILL HAVE AN IMPACT ON 
ANY COGNITIVE IMPAIRMENTS FOUND IN THE REFRACTORY JME SAMPLE. 
 
 
It is clear from past research that the cognitive deficits in JME are multi factorial, 
encompassing pathophysiology, clinical factors, treatment and psychosocial factors 
(discussed in detail in chapter four).   
 
The current thesis seeks to assess the impact of clinical and psychosocial factors on the 
neuropsychological functioning of JME patients. From the analysis of the 
neuropsychological assessments, it was found that the current sample scored more 
than one standard deviation below published norms in the three tests (digit symbol 
coding, BNT and inhibition switching). Therefore multiple linear regressions were 
conducted to assess the impact of clinical factors and mood on the scores of these three 
tests (Table 9.1, 9.2 and 9.3 summarises these regression analyses).  
 
Firstly, univariant regressions were run to investigate the contribution of each of the 
clinical and mood variables on the scores for the three tests. The variables investigated 
included age of onset, duration of epilepsy (log transformation), types of seizures, 
frequency of myoclonic seizures, frequency of GTCS, frequency of absence seizures, 
number of AEDs prescribed, HADS depression score and HADS anxiety score. The 
results of these analyses are presented in Table 9.1-9.3 below.  
 
For the following regression analyses the assumptions of homogeneity, normality and 
multicollinearity were assessed by inspection of the residual scatter plot, residual 
histogram and tolerance. Standardised residuals and Cook’s distance were checked for 
any outliers having undue influence of each model. Each of these assumptions was met 
in the analyses below.      
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Table 9.1 Univariant analysis of digit symbol coding score  
Variables Pearson’s 
correlation 
R² Sig of 
model   
beta t 
Age  .113 -.005 .402 - - 
Duration 
of epilepsy  
-.186 .017 .166 - - 
Seizures   .171 .009 .241 - - 
Myoclonic 
frequency  
-.345 .096 .029* -.750 -2.263 
Tonic 
clonic 
frequency  
-.082 .019 .615 - - 
Absence 
frequency  
-.071 -.021 .662 - - 
Number of 
AEDs 
-.403 .148 .001** -.403 -3.353 
Depression  -.206 .015 .222 - - 
Anxiety  -.218 .020 .195 - - 
*P<.05, **p<.01 
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Table 9.2 Univariant analysis of BNT score 
Variables Pearson’s  
correlation 
R² Sig of 
model   
beta t 
Age -.061 .015 .661 - - 
Duration 
of epilepsy  
-.103 .008 .460 - - 
Seizures  -.131 .005 .382 - - 
Myoclonic 
frequency  
-.159 .002 .341 - - 
Tonic 
clonic 
frequency  
-.085 .020 .612 - - 
Absence 
frequency  
 .247 .036 .129 - - 
Number of 
AEDs 
-.289 .067 .029* -3.393 -2.241 
Depression  -.068 -.025 .694 - - 
Anxiety  -.242  .031 .155 - - 
*P<.05 
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Table 9.3 Univariant analysis of inhibition switching score 
Variables Pearson’s 
correlation 
R² Sig of 
model   
beta t 
Age  .122 -.004 .380 - - 
Duration 
of epilepsy  
-.229 .034 .096 - - 
Seizures   .109 -.011 .473 - - 
Myoclonic 
frequency  
-.230 .026 .171 - - 
Tonic 
clonic 
frequency  
 .144 -.007 .395 - - 
Absence 
frequency  
-.050 -.026 .770 - - 
Number of 
AEDs 
-.229 .035 .087 - - 
Depression  -.103 -.020 .562   
Anxiety   .020 -.031 .913   
 
 
The univariant regressions revealed that the frequency of myoclonic seizures and 
number of AEDs prescribed were significant independent predictors of performance on 
the digit symbol coding test. A multivariable regression with forward variable selection 
was then run to investigate the contribution of these two significant variables (number 
of AEDs and frequency of myoclonic seizures) on the participants’ digit symbol coding 
score. This analysis revealed that only the number of AEDs prescribed was entered into 
the regression and explained 31.1% of the variance. The beta value indicated a negative 
association; therefore being on polytherapy was associated with a lower score on the 
digit symbol coding test.  
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Table 9.4 Forward multivariable regression analysis of digit symbol coding score 
Variables 
entered  
Pearson’s 
correlation 
R² Sig of 
model   
beta t 
Number 
of AEDs 
-.606 .331 .005* -.606 -3.228 
*P<.01 
 
 
The univariant regression analyses revealed only one significant independent predictor 
of naming ability, therefore a multivariable regression was not conducted. Number of 
AEDs explained 6.7% of the variance in naming ability. The beta value indicated a 
negative association; therefore being on polytherapy was associated with a lower 
naming ability. 
 
On further inspection of the results it was found that the number of AEDs prescribed 
was a significant independent predictor of naming ability (p =.007), and explained 
17.9% of the variance in performance on the BNT. The beta value indicated a negative 
association; therefore being on polytherapy was associated with low naming ability.  
 
Post-hoc independent t-tests revealed that patients on polytherapy performed 
significantly worse than those on one AED (p= .007). The means indicated that patients 
on one AED scored close to healthy means (mean= 52.5), while patients on polytherapy 
scored more than two standard deviations below healthy means (mean= 46.3). These 
results indicate polytherapy is associated with impaired naming ability.  
 
The univariant regressions revealed that none of the clinical or mood variables 
assessed significantly predicted inhibition switching score. Thus unknown variables 
are contributing to the impairment in inhibiting the natural response and the mental 
flexibility to switch between rules.  
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9.1 SUMMARY OF CHAPTER NINE 
 
The current chapter has investigated the impact of clinical characteristics and 
psychosocial variables on cognition. The regression analyses revealed the key 
contributory factor was number of AEDs prescribed, indicating that receiving 
polytherapy is associated with worse neuropsychological functioning.  
 
No clinical or mood variable significantly explained the variance in the consistently 
found impairment in switching between inhibiting a response and not inhibiting a 
response. The final two results chapters will investigate the impact of mood further and 
finally the impact of personality traits. 
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CHAPTER TEN- PSYCHIATRIC SYMPTOMS AND 
NEUROPSYCHOLOGICAL FUNCTIONING 
 
 
Hypothesis three: Refractory JME patients with high levels of anxiety and/or 
depression will be more impaired on neuropsychological functioning than those 
with normal levels of anxiety and/or depression 
 
Both depression and anxiety have been found to be associated with neuropsychological 
impairments [112].  JME patients have been reported to have high levels of depression 
and anxiety [27]. Thus to investigate whether high levels of anxiety and/or depression 
in JME is associated with neuropsychological impairments, the HADS was administered.  
 
Forty-nine percent of the patients scored in the moderate to severe range for anxiety 
symptoms and 16% for depressive symptoms. Nine (24%) people had mild anxiety; 15 
(41%) people had moderate anxiety; and three (8.1%) had severe anxiety symptoms. In 
contrast, seven (19%) people had mild depressive symptoms; five (14%) had moderate 
depressive symptoms; and one (2.7%) had severe depressive symptoms.  
 
 
Figure 10.1 Level of anxiety across the refractory JME sample 
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Figure 10.2 Level of depression across the refractory JME sample 
 
 
Higher anxiety scores were significantly correlated with poorer function on tests of 
vocabulary, similarities, information, picture completion, verbal IQ, performance IQ, 
full-scale IQ, and letter fluency. Independent t-tests revealed significantly poorer 
function on the WAIS subtests vocabulary (p = .004) and information (p = .010). People 
with high anxiety scores had, on average, 2.77 points lower on vocabulary (d =1.02) 
and 2.40 points lower on the information subtest (d=0.89) compared with people with 
drug-refractory JME and less extreme HADS anxiety scores. Anxiety remained a 
significant independent predictor of performance on the information subtest when 
correlated clinical and demographic characteristics (duration of epilepsy and years of 
education) were controlled for and explained 19% (p = .003) of the variance. No clinical 
or demographic characteristics significantly correlated with performance on the 
information subtest.  
 
Although the other test scores were not statistically significant, the real-life difference 
may be substantial, and medium effect sizes were found. People with high anxiety 
scores had, on average, 9.10 points lower on verbal IQ (d = 0.627, p = .065) and 9.00 
points lower on full-scale IQ (d = 0.654, p = .058) compared with people with lower 
anxiety scores. Higher depression scores were significantly correlated with poorer 
function on category fluency. Independent t-tests revealed a non-significant difference; 
however, this was likely to be due to the small number of the cohort presenting with 
high depressive symptoms. People with higher depression scores had, on average, 2.97 
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points lower on category fluency (d = 0.918) compared with people with less extreme 
HADS depression scores. 
 
10.1 SUMMARY OF CHAPTER TEN 
 
A higher proportion of patients presented with high anxiety symptoms than high 
depression symptoms. Real life differences in cognitive functioning were found 
between patients with high anxiety and depressive symptoms and those with levels of 
anxiety and depression within normal range.  
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CHAPTER ELEVEN – PERSONALITY, 
NEUROPSYCHOLOGICAL FUNCTIONING AND 
EXECUTIVE FUNCTIONS 
 
 
HYPOTHESIS FOUR: PARTICIPANTS WITH AN ABNORMAL PERSONALITY TRAITS, AS 
DETERMINED BY THE EYSENCK PERSONALITY QUESTIONNAIRE-BRIEF VERSION (EPQ-BV) 
WILL BE MORE IMPAIRED ON EXECUTIVE FUNCTIONS THAN PARTICIPANTS WITH NORMAL 
PERSONALITY TRAITS.  
 
Patients with JME have been described as having abnormal personalities [27, 98, 99]. 
To investigate whether an abnormal personality is related to neuropsychological 
functioning, the EPQ-BV was administered. Participants were considered to have 
abnormal personalities if they were found to have high levels of neuroticism and/or 
low levels of extroversion.  
 
One sample t-tests (Table 11.1) were run to compare the current refractory sample 
with the mean neurosis and extroversion values reported by Sato [137]. The data file 
was dichotomised into males and females. The EPQ-BV identified that females with 
drug-refractory JME had pathologically high neuroticism scores and low extroversion 
scores (introvert trait). The males also scores in the introverted range but not in the 
pathological range for neuroticism (Table 11.1). 
 
 
Table 11.1 Current sample EPQ-BV scores compared to norms reported by Sato [137] 
 Neuroticism    Extroversion 
 Sample 
Means 
Sato 
Norms 
p value Sample 
Means 
Sato 
Norms 
p value 
Males 33.09 
(10.34) 
26.93 
(9.96) 
.076 33.72 
(12.51) 
42.58 
(9.11) 
   .041* 
Females 39.00 
(11.51) 
30.54 
(9.38) 
.001 *** 30.63  
(9.94) 
42.09 
(8.97) 
<.001 *** 
                      N=38, *P ≤.05, **P ≤.01, ***P ≤.001 
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Independent sample t-tests were run to compare the scores of those with high and 
normal neuroticism, and those with low and normal extroversion. Due to the number of 
multiple comparisons being made, and reduce the likelihood of making Type I error the 
significance level was set at p< .01. Bonferroni correction was not applied as this would 
have given too conservative a value (0.05/41= p<0.001) due to the number of 
inferential statistics conducted, and therefore would have increased the likelihood of 
making Type II error. The use of a significance level of p<.01 has been used by others 
[114, 153]. 
 
11.1 Neuroticism Vs Neuropsychological Functioning 
The impact of neuroticism on neuropsychological functioning was investigated by 
splitting the current sample in to those with ‘high neuroticism’ and those with ‘normal 
neuroticism’. Participants were considered to have abnormally high neurosis if they 
scored more than one standard deviation above the means reported [137], based on 
257 healthy volunteers. Levels of neuroticism differ in healthy males and females, with 
females exhibiting higher levels of neurosis. Therefore a score ≥40 for females and ≥37 
for males was considered abnormal in the current sample.  
 
Tables 11.2-11.3 below display the means and z-score for each test, illustrating 
whether the scores of participants in the two groups was lower than published norms. 
The p value for the comparison between the two groups (‘high’ neurosis Vs ‘normal’ 
neurosis) is also given.  
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Table 11.2 Intellectual functioning as measured by the WAIS of patients with drug-
refractory JME and high/normal levels of neuroticism compared to healthy 
standardized controls. 
Cognitive test High neuroticism Normal neuroticism 
Neurotic 
Vs non-
neurotic 
 Mean 
score 
Mean 
adjusted  
 z-score 
Mean 
score 
Mean 
adjusted 
z-scores 
Sig. 
Full Scale IQ 84.6 -1.03 90.7 -0.62 .224 
Verbal IQ  83.6 -1.09 92.0 -0.53 .072 
Performance IQ 90.1 -0.66 90.6 -0.63 .925 
Processing Speedᵅ  88.5 -0.77 81.0 -1.27 .940ᵅ 
Vocabulary 7.00 -1.00 9.23 -0.26 .021 
Similarities 7.94 -0.69 8.14 -0.62 .833 
Arithmetic  7.69 -0.77 8.45 -0.52 .304 
Digit Span 7.56 -0.81 8.82 -0.39 .173 
Information 7.06 -0.98 9.23 -0.26 .037 
Comprehension  6.50 -1.17 8.64 -0.45 .043 
Picture Completion  9.44 -0.19 9.05 -0.32 .754 
Digit Symbol-
codingᵅ 
7.50 -0.83 6.00 -1.33 .956ᵅ 
Block Design 8.27 -0.58 8.64 -0.47 .652 
Matrix Reasoning 9.00 -0.33 9.59 -0.12 .597 
Picture 
Arrangement 
8.13 -0.62 8.27 -0.58 .881 
Letter-Number 
Sequencing 
8.31 -0.56 8.59 -0.47 .815 
Symbol Search 7.31 -0.90 8.19 -0.60 .480 
ᵅ Mann-Whitney U Test 
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Table 11.3 Memory function as measured by the WMS of patients with drug-refractory 
JME and high/normal levels of neuroticism compared to healthy standardized controls. 
Cognitive test High neuroticism 
Normal 
neuroticism 
Neurotic 
Vs non-
neurotic 
 Mean 
score 
Mean 
adjusted 
z-score 
Mean 
score 
Mean 
adjusted 
z-score 
Sig. 
Immediate Memory 87.8 -0.81 89.0 -0.73 .811 
Immediate Visual 
Memory 
85.8 -0.95 85.4 -0.97 .933 
Delayed Visual Memory 87.1 -0.86 89.2 -0.72  
Immediate Auditory 
Memory 
92.8 -0.48 95.9 -0.27 .462 
Delayed Auditory 
Memory 
98.9 -0.07 100.1 0.01 .800 
Auditory Recognition 
Memory 
95.9 -0.27 100.7 0.05 .348 
General Memory 91.8 -0.55 94.9 -0.34 .529 
WMS Working Memory 88.4 -0.77 89.6 -0.69 .819 
Logical Memory: 
immediate recall 
9.25 -0.25 10.5 0.17 .811 
Logical Memory: delayed 
recall 
10.1 0.03 11.0 0.33 .377 
Verbal Paired Associates: 
immediate recall 
8.31 -0.56 8.14 -0.62 .821 
Verbal Paired Associates: 
Delayed recall 
9.63 -0.12 8.86 -0.38 .407 
Faces: immediate 
recognitionᵅ 
8.00 -0.67 8.00 -0.67 .759ᵅ 
Faces: delayed 
recognitionᵅ 
8.00 -0.67 9.00 0.33 .122ᵅ 
Family Pictures: 
immediate recall 
7.38 -0.87 7.36 -0.88 .991 
Family Pictures: delayed 
recallᵅ 
8.00 -0.67 8.00 -0.67 .797ᵅ 
Spatial Span 7.56 -0.81 7.86 -0.71 .777 
ᵅ Mann-Whitney U Test 
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People with drug-refractory JME and high neuroticism scores scored worse across the 
battery of intellect and memory than published norms and patients with neuroticism 
scores within normal limits. Patients with neuroticism scores within normal limits also 
scored worse than published norms across much of the battery.  These finding support 
the earlier finding that patients with refractory JME have lower neuropsychological 
functioning, and indicate that also having a neurotic personality exacerbates this lower 
ability. 
 
Independent sample t-tests revealed no significant difference between neurotic and 
non-neurotic patients in the number of years of education they received, age of onset, 
duration of epilepsy, the number of AEDs they were currently prescribed and levels of 
depression. People with JME and higher neuroticism scores reported more anxiety 
symptoms and more concentration and motor difficulties compared with those with 
less extreme neuroticism scores (anxiety: p = .001, d = 1.57; ABNAS concentration: p= 
.007, d= 1.18; ABNAS motor: p= .006, d= 1.41). Both groups reported their epilepsy has 
a moderate impact on their lives.  
 
 
11.2 Extroversion Vs Neuropsychological Functioning 
In order to examine whether patients with low extroversion were more impaired on 
neuropsychological functioning, the data file was dichotomised into ‘low extroversion’ 
and ‘normal extroversion’. Participants were considered to have abnormally low levels 
of extroversion if they scored more than one standard deviation below the reported 
means [137]. Levels of extroversion have not been found to differ significantly in males 
and females, therefore a score of ≤33 for both males and females was considered 
abnormal. 
 
Tables 11.4-11.5 below display the means and z-scores for each test, illustrating 
whether the scores of participants in the two groups was significantly lower than 
published norms. The p value for the comparison between the two groups (‘low’ 
extroversion Vs ‘normal’ extroversion) is also given. 
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Table 11.4 Intellectual functioning as measured by the WAIS of patients with drug-
refractory JME and low/normal levels of extroversion compared to healthy 
standardized controls. 
Cognitive test Introverted 
Normal 
extroversion 
Introvert 
Vs non-
introvert 
 Mean 
score 
Mean 
adjusted 
 z-score 
Mean 
score 
Mean 
adjusted 
z-score 
Sig. 
Full Scale IQ 86.2 -0.92 91.4 -0.57 .319 
Verbal IQ  86.3 -0.91 92.2 -0.52 .219 
Performance IQ 89.4 -0.71 92.1 -0.53 .623 
Processing Speedᵅ  84.0 -1.07 82.5 -1.17 .632ᵅ 
Vocabulary 7.96 -0.68 8.86 -0.38 .378 
Similarities 7.71 -0.76 8.64 -0.45 .329 
Arithmetic  7.88 -0.71 8.57 -0.48 .667 
Digit Span 7.92 -0.69 8.93 -0.36 .252 
Information 7.67 -0.78 9.43 -0.19 .093 
Comprehension  7.25 -0.92 8.57 -0.48 .229 
Picture Completion  9.25 -0.25 9.14 -0.29 .929 
Digit Symbol-codingᵅ 7.00 -1.00 6.00 -1.33 .988ᵅ 
Block Design 8.00 -0.67 9.29 -0.27 .115 
Matrix Reasoning 9.50 -0.17 9.07 -0.31 .708 
Picture Arrangement 7.71 -0.76 9.07 -0.31 .170 
Letter-Number 
Sequencing 
8.46 -0.51 8.50 -0.50 .971 
Symbol Search 7.26 -0.91 8.71 -0.43 .250 
ᵅ Mann-Whitney U Test 
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Table 11.5 Memory function as measured by the WMS of patients with drug-refractory 
JME and low/normal levels of extroversion compared to healthy standardized controls. 
Cognitive test Introverted 
Normal 
extroversion 
Introvert 
Vs non-
introvert 
 Mean 
score  
Mean 
adjusted 
 z-score 
Mean 
score 
Mean 
adjusted 
 z-score 
Sig. 
Immediate Memory 88.3 -0.78 88.7 -0.75 .933 
Immediate Visual 
Memory 
.85.8 -0.97 85.0 -1.00 .767 
Delayed Visual Memory 87.7 -0.82 89.3 -0.71 .767 
Immediate Auditory 
Memory 
93.8 -0.41 95.9 -0.94 .634 
Delayed Auditory 
Memory 
99.7 -0.02 99.4 -0.04 .961 
Auditory Recognition 
Memory 
98.7 -0.09 98.6 -0.09 .979 
General Memory 93.1 -0.46 94.2 -0.39 .823 
WMS Working Memory 89.0 -0.73 89.4 -0.71 .939 
Logical Memory: 
immediate recall 
9.88 -0.04 10.1 0.03 .790 
Logical Memory: delayed 
recall 
10.6 0.20 10.5 0.17 .896 
Verbal Paired Associates: 
immediate recall 
8.04 -0.65 8.50 -0.50 .565 
Verbal Paired Associates: 
Delayed recall 
9.13 -0.29 9.29 -0.24 .865 
Faces: immediate 
recognitionᵅ 
8.00 -0.67 8.50 -0.50 .540ᵅ 
Faces: delayed 
recognitionᵅ 
8.00 -0.67 9.00 -0.33 .223ᵅ 
Family Pictures: 
immediate recall 
7.54 -0.82 7.07 -0.98 .638 
Family Pictures: delayed 
recallᵅ 
9.00 -0.33 7.50 -0.83 .654ᵅ 
Spatial Span 7.67 -0.80 7.86 -0.71 .861 
ᵅ Mann-Whitney U Test 
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People with drug-refractory JME and high introversion scores scored worse across the 
battery of intellect and memory than published norms and patients with introversion 
scores within normal limits. Patients with extroversion scores within normal limits also 
scored slightly worse than published norms across much of the battery.   
 
Independent sample t-tests revealed no significant difference between introverted and 
non-introverted patients in the number of years of education they received, age of 
onset, duration of epilepsy, the number of AEDs currently prescribed, the number of 
cognitive complaints and levels of depression or anxiety. Both groups reported their 
epilepsy has a moderate impact on their lives.  
 
11.3 Executive Functions 
Tables 11.6-11.7 below display the means and z-scores for each executive function test, 
illustrating whether the scores of participants with extreme neuroticism and/or 
introversion scores was lower than published norms. The p value for the comparison 
between the groups is also given. 
 
 
Table 11.6 Executive functioning as measured by the D-KEFS and BNT of patients with 
drug-refractory JME and high/normal levels of neuroticism compared to healthy 
standardized controls. 
Cognitive test High neuroticism Normal neuroticism 
Neurotic 
Vs non-
neurotic 
 Mean 
score 
Mean 
adjusted 
 z-score 
Mean 
score 
Mean 
adjusted 
 z-score 
Sig. 
Letter fluency 6.75 -1.08 7.41 -0.86 .557 
Category fluency 7.38 -0.87 8.05 -0.65 .643 
Category switching 8.75 -0.42 9.05 -0.32 .820 
Category accuracy 9.19 -0.27 10.0 0.00 .548 
Verbal inhibition 7.53 -0.82 7.82 -0.73 .846 
Inhibition switch 6.00 -1.33 5.95 -1.35 .968 
Boston naming testᵅ 48.0 -1.92 53.5 -0.53 .312ᵅ 
ᵅMann-Whitney U Test 
 
129 
 
Table 11.6 above indicated that both groups scored >1 standard deviation below 
published norms on the inhibition switching test. Patients with high neuroticism scores 
also scored >1 standard deviation below published norms on the letter fluency test and 
BNT. Scores within the borderline range have been highlighted in bold in Table 11.6 
above.  
 
 
Table 11.7 Executive functioning as measured by the D-KEFS and BNT of patients with 
drug-refractory JME and low/normal levels of extroversion compared to healthy 
standardized controls. 
Cognitive test Introverted Normal extroversion 
Introvert 
Vs non-
introvert 
 Mean 
score 
Mean 
adjusted 
 z-score 
Mean 
score 
Mean 
adjusted 
 z-score 
Sig. 
Letter Fluency 6.79 -1.07 7.71 -0.76 .421 
Category fluency  7.38 -0.87 8.43 -0.52 .475 
Category switching 8.33 -0.56 9.93 -0.02 .225 
Category accuracy 9.04 -0.32 10.8 0.27 .151 
Verbal inhibition 7.04 -0.99 8.92 -0.36 .208 
Inhibition switching 5.91 -1.36 6.08 -1.31 .708 
Boston naming testᵅ 49.5 -1.54 54.0 -0.38 .427ᵅ 
ᵅ Mann-Whitney U Test 
 
 Table 11.7 indicated that both groups scored >1 standard deviation below published 
norms on the inhibition switching test. Patients with low extroversion scores also 
scored >1 standard deviation below published norms on the letter fluency test and 
BNT. Scores within the borderline range have been highlighted in bold in Tables 11.7 
above.  
 
The analyses presented in Table 11.6 and 11.7 above indicated that neurotic and 
introverted patients have lower executive functioning than patients with less extreme 
scores. Figures 11.1 to 11.2 were produced to illustrate any differences between 
introverted and neurotic patients. In addition patients were classified as having an 
‘abnormal’ personality if they were highly neurotic and/or introverted, and classified as 
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having a ‘normal’ personality if they scored in the normal range for neuroticism and 
extroversion. The scores of patients classified with ‘abnormal’ and ‘normal’ 
personalities are included in Figures 11.1 to 11.2  
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[ fig 11.1-Personality and executive functions line graphs to be inserted here- 
landscape] 
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[fig 11.2 Personality and executive functions line graphs to be inserted here –
landscape] 
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Figure 11.3 illustrates the difference in naming ability between patients with different 
personality traits.   
 
 
Figure 11.3: Boston Naming Test performance (median scores) of people with drug-
refractory JME and different personality traits 
 
 
11.4 Preliminary findings with the BADS 
Just over half the sample was also administered some of the subtests from the BADS. 
These included the rule shift, key search and zoo map. 
 
Rule shift – assesses perseveration and mental flexibility i.e. the ability to adjust 
behaviour to meet demands of a changing situation 
 Key search – assesses planning ability 
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Zoo map – assesses ability to plan independently and follow a pre-formulated plan, 
while abiding by a set of rules.  
 
A Pearson’s correlation was conducted to investigate whether personality, clinical 
characteristics or mood was associated with performance on the BADS. This revealed 
significant correlations between neuroticism and the raw scores on both version one (r 
= -.540, p = .038) and two (r = - .591, p = .020) of the zoo map. People with high 
neuroticism scores scored, on average, 5.00 points lower compared with people with 
drug-refractory JME and less extreme neuroticism scores (Fig. 11.5). No other variables 
were significantly correlated with the zoo map.  
 
The zoo map is an executive function test with good ecological validity, thus the 
findings presented above indicate that refractory JME patients with neurotic 
personalities may experience problems with planning and following rules in their daily 
lives. This finding warrants further study, but must be taken with caution as 
unfortunately only a small number (n=15) of individuals in the current sample were 
administered both the zoo map and the EPQ-BV.   
 
Figure 11.5: Median scores on version one and two of the Zoo Map for drug-refractory 
JME with high and low neuroticism scores.  
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11.5 Severity of executive dysfunctions  
The severity of executive dysfunctions in the current sample was assessed by 
inspection of the samples z scores (calculated using manual means). The following tests 
were used to measure six executive and attention domains:  
 Working memory, mental control of auditory-visual stimuli and attention span: 
assessed using the digit span and letter-number sequencing. 
 Visual working memory, mental control of visual-spatial stimuli and attention: 
assessed using the symbol search, digit-symbol coding and spatial span. 
 Verbal fluency: assessed using the letter fluency and  category fluency, 
 The ability to switch between categories: assessed using category switching and 
category accuracy. 
 The ability to inhibit responses to visual-verbal stimuli: assessed using the 
colour-word interference test (verbal inhibition and inhibition switch) 
 Naming ability: assessed using the Boston naming test 
 
In concordance with previous research [154, 155] a z-score of ≤-1 (one or more 
standard deviations below the manual means) on at least one of the tests within each of 
the six domains was categorised as dysfunction in relation to that domain. As naming 
ability was measured by only one test a z-score of ≤-1 on the Boston naming test was 
categorised as executive dysfunction in relation to naming ability. If two domains were 
found to meet these criteria the patient was said to have mild executive dysfunction. If 
three or four domains met the criteria the patient was said to have moderate executive 
dysfunction. If five or more domains met the criteria the patient was said to have 
severe executive dysfunction.   
 
Of the 60 refractory patients in the current sample (2 patient was excluded from this 
analysis due to missing data), 83% demonstrated a degree of executive/attentional 
dysfunction, which was moderate-severe in 66% of patients (38/58 patients). When a 
more conservative value of ≤ 2 SD below manual means were applied to each test 45% 
of the patients presented with a degree of executive dysfunction, and 28% presented 
with moderate to severe dysfunction. These percentage are lower than that previously 
reported in a JME sample [154]. However the previous study was conducted in Brazil 
thus there may be cultural differences. Moreover IQ was found to be significantly 
correlated with all of the executive function tests, and although Moschettea and 
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Valente’s sample had a very similar mean IQ as the current sample (91.5 and 89., 
respectively) the current sample received on average almost three more years of 
formal education than their sample (13 years Vs. 10.1 years). 
 
Extreme EPQ-BV scores were found to exacerbate the level of dysfunction in the 
current sample, and, when the more conservative value of two SD below published 
norms was applied, people with extreme EPQ-BV scores demonstrated the greatest 
level of executive dysfunction impairment; 54% presented with dysfunction, and 39% 
had moderate to severe dysfunction. This degree of dysfunction was not seen in any 
individual with unremarkable EPQ-BV scores; only one (8.3%) person had moderate 
dysfunction, and three (25%) had mild dysfunction. 
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11.6 SUMMARY OF CHAPTER ELEVEN 
 
The current chapter investigated whether the abnormal personality exhibited by JME 
patients is related to the neuropsychological impairments previously reported [7, 11-
14, 16].  
 
The refractory JME sample was found to be significantly introverted compared to the 
healthy means reported by Sato [129]. In addition the females were also found to be 
significantly neurotic. When patients were split into neurotic Vs non-neurotic and 
introverted Vs non-introverted significant differences in neuropsychological 
functioning were found. Both neurotic and introverted patients scored worse across 
the majority of the battery. Moreover both neurotic and introverted patients were 
found to perform in the borderline range for letter fluency and the BNT. This suggests 
the common finding of impaired letter fluency in JME samples may be due to abnormal 
personality.  
 
Preliminary analysis with the BADS revealed that the current sample scored 
significantly worse than manual means on the zoo map. Further, when the zoo map was 
correlated with personality, mood and clinical characteristics it was found that only 
neuroticism was significantly correlated with zoo map score. Post hoc analyses 
confirmed that patients with neurotic personalities perform significantly worse than 
healthy means and non-neurotic patients.  
 
Overall this chapter has highlighted that refractory JME patients experience executive 
dysfunctions. It was found that 66% of the current sample experienced moderate to 
severe executive dysfunction. However 54% of patients with extreme personality 
scores compared to 1 participant of those with normal personality scores were 
classified as having moderate to severe executive dysfunction. In addition personality 
was found to be related to executive functions commonly found in JME, and points 
towards an association between neuroticism and real life planning ability. Abnormal 
personality is associated with frontal lobe abnormalities, thus the same frontal lobe 
abnormalities may be the cause of the executive dysfunctions in this subset of JME 
patients. However, thus far no cause has been found for the consistent impairment in 
switching between inhibiting a response and not inhibiting a response.    
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CHAPTER TWELVE – SUMMARY OF RESULTS 
 
 
Overall the current sample performed worse than published norms across the battery. 
Worse performance was found even when education was controlled for.  
 
Polytherapy was found to be associated with worse performance on 
neuropsychological test and explained a proportion of the variance. Subjective effect of 
AEDs was also associated with cognitive performance.  
 
Anxiety was associated with verbal IQ, performance IQ, full scale IQ and letter fluency. 
Both anxious and non-anxious patients performed significantly worse than manual 
means, but anxious patients performed significantly worse than non-anxious patients. 
Depression was found to be associated with category fluency. Both depressed and non-
depressed patients scored significantly worse than manual means on category fluency, 
but depressed patients scored significantly worse than non-depressed patients.  
 
Introverts and neurotic patients perform worse than published norms across the 
battery and presented with the worse executive dysfunctions. 54% of patients with 
extreme personality scores compared to 1 participant of those with normal personality 
scores were classified as having moderate to severe executive dysfunction 
 
 
 
 
 
 
 
 
 
 
.  
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CHAPTER THIRTEEN – DISCUSSION 
 
 
13.1 NEUROPSYCHOLOGICAL PROFILE 
 
Several studies in the past decade have investigated the neuropsychological profile of 
JME patients. Previous research has compared JME patients to healthy controls [7, 12-
14, 72], unaffected siblings [7, 16], and patients with other epilepsy syndromes [11, 
12]. The current thesis (to the best of the author’s knowledge) was the first study to 
profile patients solely with drug refractory JME, it was expected that more impairments 
may be revealed in this sample. 
 
Following a review of the literature it was found that JME patients consistently perform 
worse across tests of intellect, memory and executive functions. However, the 
difference in performance was only consistently significant on executive function tests, 
in particular verbal fluency and inhibition. The same finding was reported by 
Wandschneider et al [16] when they reviewed the literature. The current thesis also 
supports this, finding significant impairments in both verbal fluency and inhibition.  
 
The drug-refractory JME cohort had significantly worse neuropsychological functioning 
than published norms and 66% were classified as having moderate to severe executive 
dysfunctions. A previous study [154] that applied the same criteria when examining the 
severity of executive dysfunctions found a higher percentage of patients had 
dysfunction than the current study. However, three of the six executive and attention 
tests differed between the current and Moschetta and Valente study [154], thus the 
tests administered in the earlier study may be more sensitive to the frontal 
dysfunctions in JME patients. In addition, the patients in the current study received on 
average three more years of formal education than the patients in the Moschetta study, 
which may have improved the performance of the current patients.  
 
The current sample performed worse than published norms across the majority of the 
test battery, however only three tests were found to have a z-score of <1.00 SD below 
published norms; digit-symbol coding test, inhibition switching test and BNT. This is 
inconsistent with previous studies that have also reported impairments in verbal 
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memory [12, 13]. However, when the current sample was split into those who had 11 
or more years of education, and those who had less than 11 years of education, there 
were significant differences in performance on verbal IQ, auditory immediate and 
auditory delayed memory.  
 
On inspection of the means both groups still performed within normal limits on verbal 
immediate and delayed memory, albeit patients with more years of education scored 
higher. Conversely, performance on verbal IQ for both groups was significantly lower 
than manual means. Yet those who received more years of education remained within 
normal limits, while those with <11 years education scored at the lower end of the 
below average range and <1.00 SD below published norms (z = -1.22). These results 
indicate that verbal memory is not impaired in JME, and education level is the sole 
contributor to the current samples performance. However, the current samples verbal 
IQ scores were lower despite education level, thus other factors may be involved. Other 
factors will be discussed further below.  
 
 
13.1.1 Refractory JME Vs controlled JME 
One of the aims of the current thesis was to compare refractory patients to controlled 
JME patients. Unfortunately a controlled JME group was not possible to recruit for 
reasons which will be discussed in the limitations section below. Therefore to compare 
the neuropsychological functioning of the current sample with controlled patients the 
means reported by Pascalicchio et al. [13] were used. Table 13.1 gives the p values from 
the one sample t-tests conducted.   
 
The refractory sample scored significantly lower across the majority of the subtests 
from the WAIS when compared to controlled patients. In addition the executive 
function tests revealed the current sample performed significantly worse on verbal 
inhibition and the Boston naming test. However there was no significant difference 
found between the two patient groups on the letter fluency task. 
 
Thus overall the neuropsychological functioning of the refractory patients was worse 
than Pascalicchio et al’s controlled sample. The worse performance of the current 
sample was despite them receiving significantly more years of education compared to 
the controlled JME group. On average the refractory patients received 1.62 years more 
of formal education. However there was also a significant difference between the 
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duration of epilepsy of both groups. The refractory sample had epilepsy for 7.45 years 
longer on average, which was significantly longer than the controlled patients.  
 
The results in Table 13.1 indicate that refractory patients have worse 
neuropsychological functioning compared to controlled JME patients. However it must 
be noted that the controlled patients were not matched to the current sample, and both 
the current thesis and Pascalicchio et al [13] found years of education and duration of 
epilepsy to effect performance.  
 
Table 13.1 Neuropsychological functioning of current refractory JME sample 
compared to a controlled JME sample (means reported in Pascalicchio et al [13]) 
 Current 
sample Vs 
Pascalicchio 
JME sample 
Vocabulary    .603 
Similarities < .001 
Arithmetic  < .001 
Digit Span    .001 
Information < .001 
Comprehension  < .001 
Picture Completion  < .001 
Digit Symbol-coding < .001 
Block Design < .001 
Matrix Reasoning    .001 
Picture Arrangement    .227 
LN Sequencing    .002 
Symbol Search <.001 
Letter fluency    .147 
Boston naming test < .001 
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13.2 CONTRIBUTORY FACTORS  
 
13.2.1 Clinical characteristics  
Past JME studies that have investigated the impact of clinical variables have been 
contradictory. One study concluded no clinical variable significantly predicted 
neuropsychological functioning found in JME patients [12]. A recent study found 
performance on executive function tests were significantly correlated with duration of 
epilepsy, frequency of myoclonic and GTCS [154]. Another study also found duration of 
epilepsy was associated with neuropsychological functioning [13]. They reported as the 
duration of epilepsy increased, the degree of impairment increased. In the current 
study duration of epilepsy was significantly correlated with immediate memory 
(overall and auditory), attention, visual working memory (Digit symbol coding and 
symbol search) and inhibition switching. On average, people in the current sample with 
low inhibition switching scores had JME for 8 years 8 months longer than those with 
higher inhibition switching scores. In addition, experiencing all three seizure types 
(myoclonic, GTCS and absences) was significantly correlated with worse performance 
on letter fluency and verbal inhibition.  
 
Of the three cognitive tests (digit-symbol coding, BNT and inhibition switching) that 
gave scores <1.00 SD below the published norms, number of AEDs was found to be the 
sole significant predictor of digit-symbol coding and BNT. Significant negative 
correlations were found, which indicated that polytherapy was associated with worse 
performance. In contrast a large study of refractory epilepsy found no difference 
between adverse events profiles (including cognition items) of those on monotherapy 
compared to those on polytherapy [158]. However, they did not use any objective 
measures of cognition and the sample consisted of mainly focal epilepsy patients, both 
factors making it difficult to compare to the current findings. Unfortunately, due to the 
number of different AED combinations prescribed in the current sample it was not 
possible to tease out the effects of the separate AEDs.    
 
In line with past research the current study found that measures of attention were 
more often correlated with clinical variables than executive functions. In addition 
planning and inhibition (when combined with mental flexibility) were not affected by 
clinical variables [154].  No clinical or mood variable predicted performance on 
inhibition switching, and the finding that on average all patients perform within the 
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borderline range on this test provides further support for an underlying frontal lobe 
abnormality.   
 
13.2.2 Affective symptoms 
Studies that have investigated the neuropsychiatric profiles of JME patients have found 
a high proportion of mood disorders, particularly anxiety and depression [27, 28, 96].  
 
Measures 
In the current investigation the HADS was administered to investigate anxiety and 
depression. Past studies of JME [26-28] have often chosen to use the Scheduled Clinical 
Interview for the DSM-IV axis I, but this requires a psychiatrist to administer thus is 
costly in time and money. The HADS on the other hand can be administered by anyone, 
takes the patient 10 minutes to complete and has been used in a JME study that was 
similar to the current investigation [7]. Further, a study that compared depression tools 
concluded that that the HADS should be chosen over other self-completed 
questionnaires for use with epilepsy patients [159], and it has been found to have good 
internal and test-retest reliability in non-neurological clinical groups [152]. Finally, a 
study that assessed the HADS as a screening tool found the probability of a case defined 
by the HADS being found a case using the SCID was 80%. Therefore, for the purposes of 
the current study the HADS was deemed the optimal choice.    
 
Affective symptoms and cognition  
In the current sample almost half of the patients (48.6%) were found to have moderate 
to severe levels of anxiety. Consistent with previous research, a smaller percentage of 
patients (16.2%) were found to have moderate to severe levels of depression. However, 
the percentage of patients with high levels of anxiety is higher than previously reported 
[27]. This may to be due to the current sample being drug refractory or the use of 
different assessment tools. 
 
The higher level of anxiety found in the current sample may contribute to the range of 
neuropsychological impairments found. To investigate the impact of mood on cognition 
HADS anxiety and depression scores were correlated with patients score across the 
neuropsychological battery. This revealed significant negative correlations between 
anxiety and verbal IQ, performance IQ, full scale IQ and letter fluency. In addition, the 
analysis revealed a significant negative correlation between depression and category 
fluency. Thus high levels of anxiety were correlated with lower intellect and phonetic 
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mental fluidity, and high levels of depression were associated with lower semantic 
mental fluidity.   
 
The correlations with anxiety were further investigated by dichotomising patients into 
those with ‘high anxiety’ and ‘normal anxiety’. This revealed that within the current 
refractory sample, both anxious and non-anxious patients have lower 
neuropsychological functioning than published norms. However the non-anxious group 
scored within the average range on all four cognitive measures. The anxious patients 
scored within the low average range for performance IQ, full scale IQ and verbal IQ, 
although the latter two were at the lower end of the low average range. In addition 
anxious patients scored within the borderline range for letter fluency. 
 
The regression analyses reported in chapter nine revealed that anxiety is not a 
significant independent predictor of the tests investigated, past research has found that 
anxiety is associated with health related quality of life in patients with epilepsy [160], 
therefore patients’ anxiety level should be considered when treating JME patients.   
 
Depression was also further investigated by splitting patients into two groups, namely 
‘high depression’ and ‘normal depression’. This revealed that both depressed and non-
depressed patients scored significantly lower than manual means on category fluency. 
However, on inspection of the means it was found that although the non-depressed 
patients scored lower than the published norms their performance was still within 
normal limits. Conversely, the high depression group performance was in the impaired 
range, but a significant difference was not found. However, it must be noted that the 
‘high depression’ group consisted of only six patients verses 30 in the ‘normal 
depression’ group, thus the result must be interpreted with caution. In a regression 
analysis depression was not a significant independent predicator of category fluency 
performance, but number of AEDs prescribed was and explained 18.2% of the variance 
in category fluency performance.  
 
Both anxiety and depression were not associated with current AED treatment, number 
of AEDs prescribed, age of onset, duration of epilepsy, or seizure types. This suggests 
that both anxiety and depression are at least in part associated with the underlying 
brain abnormalities in JME. 
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13.3 PERSONALITY  
 
When Janz first described JME he described the patients as immature, emotionally unstable, 
hedonistic and indifferent to their disease [65]. Since, studies have found a high percentage 
of axis II personality disorders (particularly cluster B) and axis I psychiatric disorders 
(particularly anxiety and depression) in JME samples, and significantly more than in healthy 
controls [27, 98, 99].  
 
13.3.1 Past studies  
It is unclear how anatomically bounded a function ‘personality is, but it has been  
proposed that the abnormal personality exhibited by JME patients is related to the 
frontal lobe dysfunctions reported in these patients [16, 20, 26, 97]. Previous research 
has found a reduction in grey matter volume in the thalamus and increased volume in 
the right frontal gyri in JME patients compared to healthy controls. These differences 
were exacerbated in patients with cluster B personality disorders who had further 
significant volume differences in these areas compared to JME patients without 
personality disorders [20].  
 
Other studies have investigated whether personality is related to structural  and 
functional abnormalities in the frontal lobes [20, 26] and focal epilepsies [27]. Or 
whether structural brain abnormalities [72, 82], functional brain abnormalities [22, 72] 
and focal epilepsies [11, 12] are related to neuropsychological functioning.  
 
A study that compared JME patients to patients with FLE and TLE (both focal 
epilepsies) found JME patients performed significantly worse than patients with TLE 
and healthy matched controls on verbal fluency, metal flexibility, planning and 
perseveration. When JME patients were compared to FLE no significant differences 
were found [12]. This was despite the administered tests being measures of frontal 
lobe functioning and patients with FLE having lesions in the frontal lobe. This study 
clearly indicates a frontal lobe abnormality in JME. 
 
Studies that have compared JME patients with localised epilepsies and healthy controls 
have found significant differences. One study found 70% of JME patients had an axis I 
or axis II disorder, and significantly more of each compared to healthy matched 
controls [27]. In another study they compared this JME sample to patients with TLE 
they found axis I psychiatric disorders in 50% of patients in both groups [28]. However, 
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TLE is associated with emotional problems due to lesions in the limbic region of the 
brain, thus a high percentage of mood disorders are expected. To the contrary, JME is 
an idiopathic epilepsy and by definition has no physical brain abnormalities. In this 
study they found an association between anxiety disorders and JME, and between 
psychosis and TLE. They suggested that these distinct behavioural differences may be a 
result of specific brain dysfunctions caused by the different epilepsies [28].  
 
Past research has proposed that the abnormal personality exhibited by patients with 
JME is related to the executive dysfunctions reported in these patients [16, 20, 26, 97]. 
A previous study touched on this by examining correlations between executive 
functioning and history of psychiatric disorders [154]. To the best of the author’s 
knowledge, the current thesis is the first study to investigate the relationship between 
dysexecutive functions and specific personality traits in patients with drug-refractory 
JME.  
 
 
13.3.2 Current study 
The current study found worse neuropsychological performance across the battery. 
However significant impairments were found for inhibition, mental flexibility and 
naming ability across the whole sample. The common finding of impaired verbal 
fluency was not revealed in the sample as a whole, but it was when patients were 
divided by personality traits.  
 
Neurotic patients remained impaired on the processes above in addition to impairment 
in verbal fluency. To the contrary, non-neurotic patients only remained impaired on 
inhibition and mental flexibility. Using a published method of stratifying executive 
dysfunctions in JME [154], the majority of patients, regardless of EPQ-BV scores, 
exhibited executive dysfunction. However, when a more conservative analysis was 
used, over half of the patients with JME and high EPQ-BV scores had dysfunction, with 
39% presenting with moderate to severe dysfunction. Conversely, no patient with low 
EPQ-BV scores presented with severe dysfunction, and only one participant had 
moderate dysfunction.  
 
People with drug-refractory JME and a high anxiety score had significantly poorer 
intellectual functioning and naming ability. All patients performed worse than 
published norms on naming ability, but only those with high anxiety scores performed 
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within the borderline-impaired range and those with high neuroticism scores 
performed extremely closely to this range. Preliminary findings with the BADS revealed 
significant correlations between poorer planning ability and only a high neuroticism 
score. The planning ability of those with high neuroticism scores was marginally lower 
when given the order of places to visit (zoo map version two), but when given a list of 
places to visit with no guidance on order, patients with high neuroticism scores, 
struggled considerably. As already mentioned this is only a preliminary finding due to 
the small number of patients who were administered both the BADS and the EPQ-BV. 
Thus future research is encouraged to include the zoo map in studies of JME and 
personality.  
 
Not one patient with abnormal personality traits was found to have normal 
performance across all executive functions, however only a third of patients with 
normal personality traits scored within the average to high average range across all 
executive function tests. This indicates that patients with normal personality traits also 
have impaired executive functions. However, this finding may be due to the limited 
personality traits examined in the current study. It is hoped that these findings will be 
used to highlight that abnormal personality in JME is related to patient’s frontal lobe 
functioning. If possible future research should use a more comprehensive assessment 
of personality (i.e. SCID).   
 
Further research is encouraged particularly investigating the genetic and imaging 
differences in JME patients with abnormal personality traits. The current findings 
suggest a subgroup of patients who have a more severe type of JME, which may be 
distinguished by genetic aetiology.  
 
13.4 QUALITY OF LIFE  
 
Patients with drug-refractory JME are most likely to use clinical services and represent 
the cohort of JME patients with the greatest social burden. Therefore, until more AEDs 
have been developed, treatment of refractory JME must focus on achieving the best 
quality of life possible for these patients. In the current study polytherapy was 
associated with significantly worse performance across much of the battery. In 
addition, polytherapy was associated with high levels of fatigue, which may influence 
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an individual’s ability to work. In support of this it was found that patients who were 
unemployed had significantly high levels of fatigue, whereas those who were employed 
had normal levels of fatigue. Although adequate seizure control is the main goal, a 
patient’s ability to work and their cognitive functioning must be considered. 
   
The current study and past research [27, 28] has shown high levels of anxiety are 
present in JME patients, and the current study indicates that anxiety is related to 
intellect and executive functions. Thus treating anxiety as well as the seizure may 
improve cognition and therefore quality of life.  
 
Furthermore, the current study revealed that patients with abnormal personality traits 
were impaired on verbal fluency, mental flexibility, inhibition, planning and naming 
ability. However, when patients had a normal personality, executive functions where 
improved, although mental flexibility and inhibition remained impaired.  
 
Being neurotic and/or introverted, highly anxious and having impaired executive 
functions may impact on an individual’s ability to interact with others, and may have a 
detrimental effect on their personal and working relationships. Thus more research 
must be done to elucidate the cause of abnormal personality traits and affective 
symptoms in JME, but for now treatments such as psychotherapy may improve day to 
day life.  
 
13.5 LIMITATIONS AND SUGGESTIONS FOR FUTURE STUDY 
 
The biggest limitation to the current study was not all of the patients completed the 
EPQ-BV. This was added to the battery by the author when JW joined the ReJuMEC 
project. All the patients tested by the author were administered the EPQ-BV during 
testing, and all patients already tested or tested as part of the Wales epilepsy study 
were posted a copy of the questionnaire. If it was not returned within a month a second 
copy was sent. Unfortunately despite the effort to get as many patients to complete the 
questionnaire it was not possible to get everyone to complete it.  
 
A limitation of the EPQ-BV itself is that it only assesses two dimensions of personality. 
A particular set of executive dysfunctions were found to be associated with 
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neuroticism. However not all impairments were explained by neuroticism, and some 
patients who were classified as having normal personality by the EPQ-BV were also 
found to have executive dysfunctions. Thus these patients with normal personality may 
in fact have different personality traits not assessed by the EPQ-BV. JME is a 
heterogeneous disorder and different genetic aetiologies may result in different 
personality traits and levels of impairment. Despite this the EPQ-BV has been a 
worthwhile tool for the current thesis. This is the first study that has investigated the 
relationship between specific personality traits and frontal lobe functions in drug-
refractory JME, and has revealed frontal dysfunctions are associated with personality 
traits. In addition due to the comprehensive battery administered to the patients the 
brevity of the EPQ-BV made it an appropriate choice.  
 
The current study also aimed to profile drug-refractory JME, as this has not yet been 
done, thus a long battery of assessments were required. However, it is suggested that 
future research that seeks to explore personality and frontal functions should focus the 
neuropsychological battery on executive function tests. In particular tests of mental 
flexibility, planning, inhibition, verbal fluency and naming ability should be 
administered. The executive function tests should be given in combination with a 
comprehensive personality and psychiatric assessment such as the SCID, which has 
already been shown as a valid tool in JME research [26-28]. 
 
Finally, there were several limitation related to the sample. Firstly the current study 
did not have a control group. A healthy control group was not used as the aim was to 
profile drug-refractory JME. However an additional sample of patients with controlled 
JME was desired, and data collection from such patients was attempted. However, 
patients with controlled JME very rarely have appointments at tertiary centres, which 
is where the patients for the current study were recruited. The author did attempt to 
find controlled patients by studying the medical records of every patient at the Walton 
centre who was diagnosed with JME. In addition JW attended weekly epilepsy clinics. 
Any patient that was identified through medical records or clinics was contacted by 
letter. Unfortunately only a handful of controlled patients responded to the letters and 
were tested, thus there were too few for reliable comparison with the refractory 
sample. 
 
Secondly, the size of the sample was limited by loss of funding. The original study was 
funded by the MRC and only a few months following JW joining the project the funding 
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was stopped. This limited resources and time available for JW to recruit and test 
patients for the study. As a consequence, the statistical tests conducted and their 
resulting power was limited.  
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CHAPTER FOURTEEN – SUMMARY OF THESIS 
 
 
Refractory JME patients have worse neuropsychological functioning than healthy 
controls and are impaired on attention and executive functions. Overall cognitive 
functioning within the average range (but worse than healthy controls) with specific 
frontal lobe dysfunctions is consistent with JME samples of controlled and mixed 
patients [7, 11-14, 16, 22, 106, 154].  The current study found worse performance on 
some cognitive domains, explained by: fewer years of education, polytherapy, and 
duration of epilepsy. 
 
People with drug-refractory JME performed least well on tests of mental flexibility and 
inhibition. People with the poorest naming ability also had high anxiety scores and 
reported high levels of cognitive problems. Furthermore, they had a higher mean 
neuroticism score with a small to medium effect size. People with the lowest inhibition 
switching scores had a longer duration of epilepsy and also reported high levels of 
cognitive problems. However, the whole sample was borderline impaired on inhibition 
switching. Impaired inhibition is a consistent feature in JME analysis [12, 16, 72], which 
suggests that this impairment may be caused by a fundamental structural or functional 
brain abnormality shared by all people with JME. Past studies that have assessed 
healthy siblings of patients with JME have also found that they perform worse than 
healthy unrelated controls [7]. This suggests that impaired inhibition may be 
genetically determined. The current thesis indicates that the common impairment in 
inhibition switching is exacerbated by the duration of epilepsy. 
 
When Janz first described JME patients he described their personality as “characterised 
by unsteadiness, lack of discipline, hedonism, and an indifference to their disease. ... They 
often appear self-assured and bragging, the girls and women coquettish and seducing, but 
can also act decidedly mistrusting and be timid, frightened and inhibited. ... Their mood 
changes rapidly and frequently. This makes their contact both charming and difficult. ... 
They are easy to encourage and discourage, they are gullible and unreliable.” [161]. 
Since, research has investigated the psychiatric co-morbidities of JME patients, and 
found high incidence of anxiety and personality disorders [20, 27, 28]. In support the 
current thesis also found high incidence of anxiety and abnormal personality traits.  
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Past research has investigated whether psychiatric co-morbidities are related to frontal 
functioning. People with extreme neuroticism and/or introversion scores 
demonstrated the greatest level of executive dysfunction impairment, which was not 
seen in any individual with unremarkable personality scores. The affective, personality, 
and cognitive findings indicate the sample as a whole presented with deficits in the 
inferior (inhibition) and medial (switching) frontal cortex. However, the results 
indicate a broad network failure in the frontal lobes of a high proportion of those with 
high neuroticism and/or introversion traits. Furthermore, people with drug-refractory 
JME and high anxiety scores presented with the greatest impairment in naming ability. 
Moreover, preliminary findings indicated that neurotic personality was associated with 
impaired planning ability. Thus the current thesis indicates that specific executive 
dysfunctions are related to maladaptive behaviour. Future research should examine 
whether distinct behavioural differences are a result of specific brain dysfunctions that 
result in the different levels of impairments found in JME.  
 
14.1 CONCLUSIONS 
This research was conducted in the context of the ReJuMEC study, which aimed to 
provide a comprehensive profile of drug-refractory JME. The sample as a whole 
presented with neuropsychological impairments previously reported in JME research, 
but indicated that personality traits and psychiatric symptoms were related to the 
greatest impairments, particularly in executive functions.    
 
There have been previous attempts to subcategorise JME e.g. by clinical characteristics 
[25], however due to the multiple factors and potentially multiple behavioural patterns 
it may not be possible to categorise JME into neat subcategories. Nevertheless, distinct 
behavioural patterns may be used to identify differences in frontal 
structure/functioning, and ultimately in genotype.  
 
This research has contributed to our understanding of the relationship between the 
abnormal personality traits and executive dysfunctions both of which have often been 
reported in JME research. This research has identified a possible subgroup of patients 
that present with a more severe type of JME, and may be distinguished by genetic 
stratification. Finally the current research confirms the breadth of deficits in drug-
refractory JME, and highlights that it is more than just executive function difficulties 
that must be targeted to support individuals through education and employment.  
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